Aberizk, W. J., Silver, B., Henderson, I. C., Cady, B., & Harris, J. R. (1986). The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer, 58(6), 1214-1218.
Abner, A. L., Recht, A., Eberlein, T., Come, S., Shulman, L., Hayes, D., . . . Harris, J. R. (1993). Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. Journal of clinical oncology, 11(1), 44-48. https://doi.org/10.1200/jco.1993.11.1.44
ACOG. (2014). Tamoxifen and Uterine Cancer (Committee Opinion Number 601, June 2014). Washington, DC: The American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Hentet fra https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/06/tamoxifen-and-uterine-cancer
Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martin, M., . . . Wapnir, I. L. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet. Oncology, 15(2), 156-163. https://doi.org/10.1016/s1470-2045(13)70589-8
Afghahi, A., & Kurian, A. W. (2017). The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Current treatment options in oncology, 18(5), 27. https://doi.org/10.1007/s11864-017-0468-y
Agresti, R., Martelli, G., Sandri, M., Tagliabue, E., Carcangiu, M. L., Maugeri, I., . . . Pierotti, M. A. (2014). Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer, 120(6), 885-893. https://doi.org/10.1002/cncr.28499
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., . . . Hayes, D. F. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet. Oncology, 11(1), 55-65. https://doi.org/10.1016/s1470-2045(09)70314-6
Alkis, N., Durnali, A. G., Arslan, U. Y., Kocer, M., Onder, F. O., Tokluoglu, S., . . . Altundag, K. (2011). Optimal timing of adjuvant treatment in patients with early breast cancer. Medical oncology, 28(4), 1255-1259. https://doi.org/10.1007/s12032-010-9566-4
Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., & Haffty, B. G. (2005). Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. International journal of radiation oncology, biology, physics, 63(3), 845-851. https://doi.org/10.1016/j.ijrobp.2005.02.035
Alterio, D., Jereczek-Fossa, B. A., Franchi, B., D'Onofrio, A., Piazzi, V., Rondi, E., . . . Orecchia, R. (2007). Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. International journal of radiation oncology, biology, physics, 67(1), 144-150. https://doi.org/10.1016/j.ijrobp.2006.08.051
Amant, F., Han, S. N., Gziri, M. M., Vandenbroucke, T., Verheecke, M., & Van Calsteren, K. (2015a). Management of cancer in pregnancy. Best practice & research. Clinical obstetrics & gynaecology, 29(5), 741-753. https://doi.org/10.1016/j.bpobgyn.2015.02.006
Amant, F., Loibl, S., Neven, P., & Van Calsteren, K. (2012). Breast cancer in pregnancy. Lancet, 379(9815), 570-579. https://doi.org/10.1016/s0140-6736(11)61092-1
Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., . . . Van Calsteren, K. (2015b). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. The New England journal of medicine, 373(19), 1824-1834. https://doi.org/10.1056/NEJMoa1508913
Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., . . . Loibl, S. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. Journal of clinical oncology, 31(20), 2532-2539. https://doi.org/10.1200/jco.2012.45.6335
American College of Radiology. (2007). Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. Journal of the American College of Surgeons, 205(2), 362-376. https://doi.org/10.1016/j.jamcollsurg.2007.02.057
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocana, A. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute, 103(17), 1299-1309. https://doi.org/10.1093/jnci/djr242
Anbazhagan, R., Fujii, H., & Gabrielson, E. (1999). Microsatellite instability is uncommon in breast cancer. Clinical cancer research, 5(4), 839-844.
Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., . . . Wolmark, N. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. Journal of clinical oncology, 27(15), 2466-2473. https://doi.org/10.1200/JCO.2008.19.8424
Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., . . . Langkjer, S. T. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. Journal of clinical oncology, 29(3), 264-271. https://doi.org/10.1200/Jco.2010.30.8213
Andre, F., Broglio, K., Roche, H., Martin, M., Mackey, J. R., Penault-Llorca, F., . . . Pusztai, L. (2008). Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. Journal of clinical oncology, 26(16), 2636-2643. https://doi.org/10.1200/JCO.2007.14.9146
Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., . . . Group, S.-S. (2019a). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine, 380(20), 1929-1940. https://doi.org/10.1056/NEJMoa1813904
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., . . . Rugo, H. S. (2021). Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Annals of oncology, 32(2), 208-217. https://doi.org/10.1016/j.annonc.2020.11.011
Andre, F., Ismaila, N., Henry, N. L., Somerfield, M. R., Bast, R. C., Barlow, W., . . . Stearns, V. (2019b). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. Journal of clinical oncology, 37(22), 1956-1964. https://doi.org/10.1200/jco.19.00945
Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., . . . Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American journal of human genetics, 72(5), 1117-1130. https://doi.org/10.1086/375033
Appelt, A. L., Vogelius, I. R., & Bentzen, S. M. (2013). Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clinical oncology (Royal College of Radiologists (Great Britain)), 25(3), 147-152. https://doi.org/10.1016/j.clon.2012.07.012
Arthur, D. W., Winter, K. A., Kuerer, H. M., Haffty, B., Cuttino, L., Todor, D. A., . . . White, J. R. (2020). Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA oncology, 6(1), 75-82. https://doi.org/10.1001/jamaoncol.2019.4320
Arver, B., Isaksson, K., Atterhem, H., Baan, A., Bergkvist, L., Brandberg, Y., . . . Sandelin, K. (2011). Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Annals of surgery, 253(6), 1147-1154. https://doi.org/10.1097/SLA.0b013e318214b55a
Ashkanani, F., Sarkar, T., Needham, G., Coldwells, A., Ah-See, A. K., Gilbert, F. J., . . . Heys, S. D. (2001). What is achieved by mammographic surveillance after breast conservation treatment for breast cancer? Am J Surg, 182(3), 207-210. https://doi.org/10.1016/s0002-9610(01)00704-8
Association of Breast Surgery, The British Association of Plastic, Reconstructive and Aesthetic Surgeons, & The British Association of Aesthetic Plastic Surgeons. (2012). Lipomodelling Guidelines for Breast Surgery. London: ABS, BAPRAS og BAAPS. Hentet fra http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/2012-august-lipomodelling-guidelines-for-breast-surgery.pdf?sfvrsn=0; 2012
Aubert, R. E., Stanek, E. J., Yao, J., Teagarden, J. R., Subar, M., Epstein, R. S., . . . Flockhart, D. A. (2009). Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of clinical oncology, 27(18 suppl), abstract CRA508.
Avila, A., Bartholomew, A. J., Sosin, M., Deldar, R., Griffith, K. F., Willey, S. C., . . . Tousimis, E. A. (2020). Acute Postoperative Complications in Prepectoral versus Subpectoral Reconstruction following Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 146(6), 715e-720e. https://doi.org/10.1097/PRS.0000000000007326
Azim, H. A., Jr., Santoro, L., Russell-Edu, W., Pentheroudakis, G., Pavlidis, N., & Peccatori, F. A. (2012a). Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treatment Reviews, 38(7), 834-842. https://doi.org/10.1016/j.ctrv.2012.06.004
Azim, A. A., Costantini-Ferrando, M., & Oktay, K. (2012b). Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study. Journal of clinical oncology, 26(16), 2630-2635. https://doi.org/10.1200/JCO.2007.14.8700
Aziz, S., Wik, E., Knutsvik, G., Klingen, T. A., Chen, Y., Davidsen, B., . . . Akslen, L. A. (2017). Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE, 12(2), e0171853. https://doi.org/10.1371/journal.pone.0171853
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J. M., Freyer, G., . . . Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of clinical oncology, 30(22), 2718-2724. https://doi.org/10.1200/JCO.2011.39.0708
Bailey, A. G., Brown, J. N., & Hammond, J. M. (2021). Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review. Journal of oncology pharmacy practice, 27(1), 156-164. https://doi.org/10.1177/1078155220959431
Baker, N. F., Baecher, K. M., Hart, A. M., Styblo, T. M., Carlson, G. W., & Losken, A. (2020). The impact of axillary node surgery on outcomes following immediate breast reconstruction. The breast journal, 26(11), 2170-2176. https://doi.org/10.1111/tbj.14070
Baltzer, P., Mann, R. M., Iima, M., Sigmund, E. E., Clauser, P., Gilbert, F. J., . . . Le Bihan, D. (2020). Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. European radiology, 30(3), 1436-1450. https://doi.org/10.1007/s00330-019-06510-3
Banke, A., Fosbøl, E. L., Møller, J. E., Gislason, G. H., Andersen, M., Bernsdorf, M., . . . Ejlertsen, B. (2018). Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. European journal of heart failure, 20(10), 1447-1453. https://doi.org/10.1002/ejhf.1168
Banuelos, J., Sabbagh, M. D., Roh, S. G., Nguyen, M. T., Lemaine, V., Tran, N. V., . . . Sharaf, B. (2019). Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. Plastic and reconstructive surgery, 144(6), 1270-1277. https://doi.org/10.1097/PRS.0000000000006202
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., . . . Rugo, H. S. (2021). Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England journal of medicine, 384(16), 1529-1541. https://doi.org/10.1056/NEJMoa2028485
Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., . . . Pierart, M. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. The New England journal of medicine, 345(19), 1378-1387. https://doi.org/10.1056/NEJMoa010874
Bartelink, H., Horiot, J. C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., . . . Collette, L. (2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. Journal of clinical oncology, 25(22), 3259-3265.
Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., . . . Collette, L. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. The Lancet. Oncology, 16(1), 47-56. https://doi.org/10.1016/s1470-2045(14)71156-8
Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 Suppl 1, 12-19. https://doi.org/16/suppl_1/12 [pii]
10.1634/theoncologist.2011-S1-12
Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., . . . Hortobagyi, G. N. (2012a). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England journal of medicine, 366(6), 520-529. https://doi.org/10.1056/NEJMoa1109653
Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., . . . Swain, S. M. (2012b). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine, 366(2), 109-119. https://doi.org/10.1056/NEJMoa1113216
Baselga, J., Im, S. A., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., . . . Campone, M. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(7), 904-916. https://doi.org/10.1016/S1470-2045(17)30376-5
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., . . . Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of clinical oncology, 19(5), 1444-1454. https://doi.org/10.1200/JCO.2001.19.5.1444
Beck, T. M., Hart, N. E., Woodard, D. A., & Smith, C. E. (1983). Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. Journal of clinical oncology, 1(6), 400-405. https://doi.org/10.1200/JCO.1983.1.6.400
Bentzen, S. M., Agrawal, R. K., Aird, E. G., Barrett, J. M., Barrett-Lee, P. J., Bentzen, S. M., . . . Yarnold, J. R. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, 371(9618), 1098-1107.
Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382), 419-427. https://doi.org/10.1016/s0140-6736(03)14065-2
Beresford, M., Tumur, I., Chakrabarti, J., Barden, J., Rao, N., & Makris, A. (2011). A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 23(3), 209-215. https://doi.org/10.1016/j.clon.2010.11.005
Bernstein, J. L., Teraoka, S., Southey, M. C., Jenkins, M. A., Andrulis, I. L., Knight, J. A., . . . Concannon, P. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Human mutation, 27(11), 1122-1128. https://doi.org/10.1002/humu.20415
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., . . . Winer, E. P. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 295(14), 1658-1667. https://doi.org/10.1001/jama.295.14.1658
Bidard, F. C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., . . . Bardia, A. (2022). Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology, 40(28), 3246-3256. https://doi.org/10.1200/jco.22.00338
Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., . . . Audisio, R. (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The Lancet. Oncology, 13(4), e148-e160. https://doi.org/10.1016/S1470-2045(11)70383-7
Bijker, N., Donker, M., Wesseling, J., den Heeten, G. J., & Rutgers, E. J. (2013). Is DCIS breast cancer, and how do I treat it? Current treatment options in oncology, 14(1), 75-87.
Bijker, N., Meijnen, P., Peterse, J. L., Bogaerts, J., Van Hoorebeeck, I., Julien, J. P., . . . Rutgers, E. J. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of clinical oncology, 24(21), 3381-3387. https://doi.org/10.1200/Jco.2006.06.1366
Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C., . . . van de Vijver, M. J. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. Journal of clinical oncology, 19(8), 2263-2271. https://doi.org/10.1200/JCO.2001.19.8.2263
Bines, J., Oleske, D. M., & Cobleigh, M. A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of clinical oncology, 14(5), 1718-1729. https://doi.org/10.1200/JCO.1996.14.5.1718
Bliss, J. M., Kilburn, L. S., Coleman, R. E., Forbes, J. F., Coates, A. S., Jones, S. E., . . . Coombes, R. C. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. Journal of clinical oncology, 30(7), 709-717. https://doi.org/10.1200/JCO.2010.33.7899
Blohmer, J. U., Link, T., Reinisch, M., Just, M., Untch, M., Stötzer, O., . . . Loibl, S. (2022). Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA oncology, 8(7), 1010-1018. https://doi.org/10.1001/jamaoncol.2022.1059
Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., . . . van de Velde, C. J. H. (2018). Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 110(1). https://doi.org/10.1093/jnci/djx134
Blough, J. T., Vu, M. M., Qiu, C. S., Mlodinow, A. S., Khavanin, N., Fine, N. A., & Kim, J. Y. S. (2018). Beyond 30 Days: A Risk Calculator for Longer Term Outcomes of Prosthetic Breast Reconstruction. Plastic and reconstructive surgery. Global open, 6(12), e2065. https://doi.org/10.1097/gox.0000000000002065
Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001). Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92(7), 1759-1768. https://doi.org/10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jr., Jacobs, S. A., . . . Wolmark, N. (2017). Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of clinical oncology, 35(23), 2647-2655. https://doi.org/10.1200/jco.2016.71.4147
Blumgart, E. I., Uren, R. F., Nielsen, P. M., Nash, M. P., & Reynolds, H. M. (2011). Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast cancer research and treatment, 130(2), 699-705. https://doi.org/10.1007/s10549-011-1737-2
Body, J. J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., . . . Bergstrom, B. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of oncology, 14(9), 1399-1405. https://doi.org/10.1093/annonc/mdg367
Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., . . . Bergstrom, B. (2004). Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British Journal of Cancer, 90(6), 1133-1137. https://doi.org/10.1038/sj.bjc.6601663
Bonneterre, J., Roche, H., Kerbrat, P., Bremond, A., Fumoleau, P., Namer, M., . . . Chapelle-Marcillac, I. (2005). Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. Journal of clinical oncology, 23(12), 2686-2693. https://doi.org/10.1200/JCO.2005.05.059
Bookman, M. A., & Longo, D. L. (1986). Concomitant illness in patients treated for Hodgkin's disease. Cancer Treatment Reviews, 13(2), 77-111. https://doi.org/10.1016/0305-7372(86)90015-0
Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., . . . Obrecht, J. P. (1994). First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 12(10), 2071-2077. https://doi.org/10.1200/JCO.1994.12.10.2071
Borud, E. K., Alraek, T., & White, A. (2010). The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause, 17(2), 262-268. https://doi.org/10.1097/gme.0b013e3181c07275
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., . . . Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery, 3(2), 224-237. https://doi.org/10.1158/2159-8290.CD-12-0349
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A. T., & Vlastos, G. (2007). Older female cancer patients: importance, causes, and consequences of undertreatment. Journal of clinical oncology, 25(14), 1858-1869. https://doi.org/10.1200/JCO.2006.10.4208
Brackstone, M., Baldassarre, F. G., Perera, F. E., Cil, T., Chavez Mac Gregor, M., Dayes, I. S., . . . Eisen, A. F. (2021). Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of clinical oncology, 39(27), 3056-3082. https://doi.org/10.1200/jco.21.00934
Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., . . . Easton, D. F. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. The New England journal of medicine, 384(5), 428-439. https://doi.org/10.1056/NEJMoa1913948
Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (red.). (2017). TNM: classification of malignant tumours (8. utg.). Oxford; Hoboken, NJ: John Wiley & Sons.
Brinton, L. A., Key, T. J., Kolonel, L. N., Michels, K. B., Sesso, H. D., Ursin, G., . . . Cook, M. B. (2015). Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. Journal of clinical oncology, 33(18), 2041-2050. https://doi.org/10.1200/jco.2014.59.1602
Brodowicz, T., Kostler, W. J., Moslinger, R., Tomek, S., Vaclavik, I., Herscovici, V., . . . Zielinski, C. C. (2000). Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 9(6), 338-342. https://doi.org/10.1054/brst.2000.0170
Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., . . . Paci, E. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. Journal of medical screening, 19 Suppl 1, 14-25. https://doi.org/10.1258/jms.2012.012078
Broglio, K. R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S. M., . . . Berry, D. A. (2016). Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA oncology, 2(6), 751-760. https://doi.org/10.1001/jamaoncol.2015.6113
Brohet, R. M., Velthuizen, M. E., Hogervorst, F. B., Meijers-Heijboer, H. E., Seynaeve, C., Collee, M. J., . . . Resource, H. (2014). Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of medical genetics, 51(2), 98-107. https://doi.org/10.1136/jmedgenet-2013-101974
Browall, M., Forsberg, C., & Wengström, Y. (2017). Assessing patient outcomes and cost-effectiveness of nurse-led follow-up for women with breast cancer - have relevant and sensitive evaluation measures been used? Journal of clinical nursing, 26(13-14), 1770-1786. https://doi.org/10.1111/jocn.13496
Brown, T., Cruickshank, S., & Noblet, M. (2021). Specialist breast care nurses for support of women with breast cancer. Cochrane database of systematic reviews, 2(2), CD005634. https://doi.org/10.1002/14651858.CD005634.pub3
Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., . . . Perez, E. A. (2012). Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer, 118(5), 1192-1201. https://doi.org/10.1002/cncr.26313
Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., . . . Bliss, J. M. (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-118. https://doi.org/10.1016/j.radonc.2016.02.027
Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., . . . Sclafani, L. M. (2006). Locoregional recurrence after mastectomy: incidence and outcomes. Journal of the American College of Surgeons, 203(4), 469-474. https://doi.org/10.1016/j.jamcollsurg.2006.06.015
Buchholz, T. A., Tucker, S. L., Masullo, L., Kuerer, H. M., Erwin, J., Salas, J., . . . Hortobagyi, G. N. (2002). Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. Journal of clinical oncology, 20(1), 17-23. https://doi.org/10.1200/Jco.20.1.17
Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., . . . Thurlimann, B. (2019). Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Annals of oncology, 30(10), 1541-1557. https://doi.org/10.1093/annonc/mdz235
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., . . . Gnant, M. (2021a). Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of oncology, 32(10), 1216-1235. https://doi.org/10.1016/j.annonc.2021.06.023
Burstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., . . . Rugo, H. S. (2021b). Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology, 39(35), 3959-3977. https://doi.org/10.1200/jco.21.01392
Butt, D. A., Lock, M., Lewis, J. E., Ross, S., & Moineddin, R. (2008). Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause, 15(2), 310-318. https://doi.org/10.1097/gme.0b013e3180dca175
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., . . . Narod, S. A. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast cancer research and treatment, 147(2), 401-405. https://doi.org/10.1007/s10549-014-3100-x
Baak, J. P., van Diest, P. J., Janssen, E. A., Gudlaugsson, E., Voorhorst, F. J., van der Wall, E., & Vermorken, J. B. (2008). Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Annals of oncology, 19(4), 649-654. https://doi.org/10.1093/annonc/mdm535
Baak, J. P., van Diest, P. J., Voorhorst, F. J., van der Wall, E., Beex, L. V., Vermorken, J. B., . . . Gudlaugsson, E. (2007). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. European journal of cancer, 43(3), 527-535. https://doi.org/10.1016/j.ejca.2006.10.001
Cabioglu, N., Hunt, K. K., Buchholz, T. A., Mirza, N., Singletary, S. E., Kuerer, H. M., . . . Meric-Bernstam, F. (2005). Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer, 104(1), 20-29. https://doi.org/10.1002/cncr.21121
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . . . Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389(10075), 1195-1205. https://doi.org/10.1016/s0140-6736(16)32616-2
Campbell, E. J., & Romics, L. (2017). Oncological safety and cosmetic outcomes in oncoplastic breast conservation surgery, a review of the best level of evidence literature. Breast Cancer: Targets and Therapy, 9, 521-530. https://doi.org/10.2147/bctt.s113742
Caplin, D. A., Calobrace, M. B., Wixtrom, R. N., Estes, M. M., & Canady, J. W. (2021). MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 556-566. https://doi.org/10.1097/PRS.0000000000007635
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., . . . Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology, 30(8), 1194-1220. https://doi.org/10.1093/annonc/mdz173
Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. The New England journal of medicine, 375(8), 717-729. https://doi.org/10.1056/NEJMoa1602253
Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., & Simes, J. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews, (2), CD003372. https://doi.org/10.1002/14651858.CD003372.pub3
Casella, D., Di Taranto, G., Marcasciano, M., Lo Torto, F., Barellini, L., Sordi, S., . . . Ribuffo, D. (2019a). Subcutaneous expanders and synthetic mesh for breast reconstruction: Long-term and patient-reported BREAST-Q outcomes of a single-center prospective study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 72(5), 805-812. https://doi.org/10.1016/j.bjps.2018.12.018
Casella, D., Di Taranto, G., Onesti, M. G., Greco, M., & Ribuffo, D. (2019b). A retrospective comparative analysis of risk factors and outcomes in direct-to-implant and two-stages prepectoral breast reconstruction: BMI and radiotherapy as new selection criteria of patients. European journal of surgical oncology, 45(8), 1357-1363. https://doi.org/10.1016/j.ejso.2019.02.009
Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., . . . Gaedigk, A. (2020). Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and translational science, 13(1), 116-124. https://doi.org/10.1111/cts.12692
Chan, A., Martin, M., Untch, M., Gil, M. G., Guillem-Porta, V., Wojtukiewicz, M., . . . Petruzelka, L. (2006). Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer, 95(7), 788-793. https://doi.org/10.1038/sj.bjc.6603351
Chan, E. K., Woods, R., Virani, S., Speers, C., Wai, E. S., Nichol, A., . . . Tyldesley, S. (2012). Accelerated hypofractionated versus conventional whole breast radiotherapy for localised left-sided breast cancer: the effect on long-term cardiac morbidity. Cancer Research, 72(24 Suppl 3), Abstract nr PD04-02. https://doi.org/10.1158/0008-5472.Sabcs12-Pd04-02
Chan, R. J., Teleni, L., McDonald, S., Kelly, J., Mahony, J., Ernst, K., . . . Yates, P. (2020). Breast cancer nursing interventions and clinical effectiveness: a systematic review. BMJ Support Palliat Care, 10(3), 276-286. https://doi.org/10.1136/bmjspcare-2019-002120
Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004). Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of oncology, 15(10), 1527-1534. https://doi.org/10.1093/annonc/mdh393
Chan, S. W., Cheung, P. S., & Lam, S. H. (2010). Cosmetic outcome and percentage of breast volume excision in oncoplastic breast conserving surgery. World journal of surgery, 34(7), 1447-1452. https://doi.org/10.1007/s00268-009-0278-x
Chang, C. C., Elliott, T. A., Wright, G., Shapiro, D. B., Toledo, A. A., & Nagy, Z. P. (2013). Prospective controlled study to evaluate laboratory and clinical outcomes of oocyte vitrification obtained in in vitro fertilization patients aged 30 to 39 years. Fertility and Sterility, 99(7), 1891-1897. https://doi.org/10.1016/j.fertnstert.2013.02.008
Chao, S. T., De Salles, A., Hayashi, M., Levivier, M., Ma, L., Martinez, R., . . . Sahgal, A. (2018). Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline. Neurosurgery, 83(3), 345-353. https://doi.org/10.1093/neuros/nyx522
Chen, J., Zhang, X., Lu, Y., Zhang, T., Ouyang, Z., & Sun, Q. (2021). Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. Breast Cancer, 28(3), 630-643. https://doi.org/10.1007/s12282-020-01196-8
Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A., Stefanick, M. L., . . . Prentice, R. L. (2015). Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA oncology, 1(3), 296-305. https://doi.org/10.1001/jamaoncol.2015.0494
Chong, A., Weinstein, S. P., McDonald, E. S., & Conant, E. F. (2019). Digital Breast Tomosynthesis: Concepts and Clinical Practice. Radiology, 292(1), 1-14. https://doi.org/10.1148/radiol.2019180760
Chua, B. H., Link, E. K., Kunkler, I. H., Whelan, T. J., Westenberg, A. H., Gruber, G., . . . Olivotto, I. A. (2022). Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet, 400(10350), 431-440. https://doi.org/10.1016/s0140-6736(22)01246-6
Cintolo-Gonzalez, J. A., Braun, D., Blackford, A. L., Mazzola, E., Acar, A., Plichta, J. K., . . . Hughes, K. S. (2017). Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4247-z
Clarke, C. N., Cortina, C. S., Fayanju, O. M., Dossett, L. A., Johnston, F. M., & Wong, S. L. (2021). Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care. Annals of surgical oncology, Jun 7 [epub ahead of print]. https://doi.org/10.1245/s10434-021-10217-5
Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., . . . Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7
Clarke, M. J. (2002). Radiotherapy for early breast cancer. Cochrane database of systematic reviews, (2), CD003647.
Clough, K. B., Lewis, J. S., Couturaud, B., Fitoussi, A., Nos, C., & Falcou, M. C. (2003). Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Annals of surgery, 237(1), 26-34. https://doi.org/10.1097/01.sla.0000041230.77663.22
Cloyd, J. M., Hernandez-Boussard, T., & Wapnir, I. L. (2013). Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Annals of surgical oncology, 20(5), 1545-1550. https://doi.org/10.1245/s10434-013-2918-5
Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., . . . Giorgi, R. (2012). Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of oncology, 23(4), 882-890. https://doi.org/10.1093/annonc/mdr330
Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., . . . Goldhirsch, A. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of clinical oncology, 25(5), 486-492. https://doi.org/10.1200/Jco.2006.08.8617
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., . . . Senn, H. J. (2015). Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology, 26(8), 1533-1546. https://doi.org/10.1093/annonc/mdv221
Cobo, A., Garcia-Velasco, J., Domingo, J., Pellicer, A., & Remohi, J. (2018). Elective and Onco-fertility preservation: factors related to IVF outcomes. Human reproduction, 33(12), 2222-2231. https://doi.org/10.1093/humrep/dey321
Cocco, E., Scaltriti, M., & Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature reviews. Clinical oncology, 15(12), 731-747. https://doi.org/10.1038/s41571-018-0113-0
Cochrane, R. A., Valasiadou, P., Wilson, A. R., Al-Ghazal, S. K., & Macmillan, R. D. (2003). Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. The British journal of surgery, 90(12), 1505-1509. https://doi.org/10.1002/bjs.4344
Cold, S., Cold, F., Jensen, M. B., Cronin-Fenton, D., Christiansen, P., & Ejlertsen, B. (2022). Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. Journal of the National Cancer Institute, 114(10), 1347-1354. https://doi.org/10.1093/jnci/djac112
Cold, S., During, M., Ewertz, M., Knoop, A., & Møller, S. (2005). Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). British Journal of Cancer, 93(6), 627-632.
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., . . . Chan, A. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. The Lancet. Oncology, 21(1), 60-72. https://doi.org/10.1016/s1470-2045(19)30687-4
Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., . . . Bell, R. (2011). Breast-cancer adjuvant therapy with zoledronic acid. The New England journal of medicine, 365(15), 1396-1405.
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., . . . Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390(10099), 1048-1060. https://doi.org/10.1016/s0140-6736(17)31145-5
Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., . . . Goldhirsch, A. (2000). Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of clinical oncology, 18(3), 584-590. https://doi.org/10.1200/Jco.2000.18.3.584
Collins, L. C., Achacoso, N., Haque, R., Nekhlyudov, L., Fletcher, S. W., Quesenberry, C. P., Jr., . . . Habel, L. A. (2013). Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast cancer research and treatment, 139(2), 453-460. https://doi.org/10.1007/s10549-013-2539-5
Colwell, A. S., & Taylor, E. M. (2020). Recent Advances in Implant-Based Breast Reconstruction. Plastic and reconstructive surgery, 145(2), 421e-432e. https://doi.org/10.1097/PRS.0000000000006510
Conte, P. F., Gennari, A., Landucci, E., & Orlandini, C. (2000). Role of epirubicin in advanced breast cancer. Clinical breast cancer, 1(Suppl 1), S46-S51. https://doi.org/10.3816/cbc.2000.s.009
Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., . . . Bliss, J. M. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369(9561), 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., . . . von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384(9938), 164-172. https://doi.org/10.1016/s0140-6736(13)62422-8
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., . . . Schmid, P. (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817-1828. https://doi.org/10.1016/s0140-6736(20)32531-9
Cortés, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., . . . Hurvitz, S. A. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. The New England journal of medicine, 386(12), 1143-1154. https://doi.org/10.1056/NEJMoa2115022
Cortes, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., . . . Hurvitz, S. A. (2021). LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of oncology, 32(Suppl 5), S1287-S1288. https://doi.org/10.1016/j.annonc.2021.08.2087
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., . . . Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 377(9769), 914-923. https://doi.org/10.1016/S0140-6736(11)60070-6
Cortes, J., Rugo, H. S., Cescon, D. W., Im, S. A., Yusof, M. M., Gallardo, C., . . . Schmid, P. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. The New England journal of medicine, 387(3), 217-226. https://doi.org/10.1056/NEJMoa2202809
Cramp, F., & Daniel, J. (2008). Exercise for the management of cancer-related fatigue in adults. Cochrane database of systematic reviews, (2), CD006145. https://doi.org/10.1002/14651858.CD006145.pub2
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., . . . Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology, 17(4), 425-439. https://doi.org/10.1016/s1470-2045(15)00613-0
Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., . . . Muss, H. (2007). Breast cancer in the elderly. Journal of clinical oncology, 25(14), 1882-1890. https://doi.org/10.1200/JCO.2006.10.2079
Curigliano, G., Burstein, H. J., E, P. W., Gnant, M., Dubsky, P., Loibl, S., . . . Xu, B. (2017). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology, 28(8), 1700-1712. https://doi.org/10.1093/annonc/mdx308
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet. Oncology, 11(12), 1135-1141. https://doi.org/10.1016/S1470-2045(10)70257-6
Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., . . . Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378(9804), 1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., . . . Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England journal of medicine, 368(11), 987-998. https://doi.org/10.1056/NEJMoa1209825
Darby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005). Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. The Lancet. Oncology, 6(8), 557-565. https://doi.org/10.1016/S1470-2045(05)70251-5
Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., . . . Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-784. https://doi.org/10.1016/S0140-6736(11)60993-8
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., . . . Peto, R. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805-816.
de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., . . . den Heijer, M. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ, 365, l1652. https://doi.org/10.1136/bmj.l1652
de Bock, G. H., Bonnema, J., van der Hage, J., Kievit, J., & van de Velde, C. J. (2004). Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. Journal of clinical oncology, 22(19), 4010-4018. https://doi.org/10.1200/jco.2004.06.080
de Boer, R., Bundred, N., Eidtmann, H., Neven, P., von Minckwitz, G., Martin, N., . . . Coleman, R. (2011). Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. (Abstract [S1-3] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-3
de Boniface, J., Szulkin, R., & Johansson, A. L. V. (2021). Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA surgery, 156(7), 628-637. https://doi.org/10.1001/jamasurg.2021.1438
de Gregorio, A., Janni, W., Friedl, T. W. P., Nitz, U., Rack, B., Schneeweiss, A., . . . Harbeck, N. (2022). The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer, 126(12), 1715-1724. https://doi.org/10.1038/s41416-021-01690-6
De La Cruz, L., Blankenship, S. A., Chatterjee, A., Geha, R., Nocera, N., Czerniecki, B. J., . . . Fisher, C. S. (2016). Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Annals of surgical oncology, 23(10), 3247-3258. https://doi.org/10.1245/s10434-016-5313-1
de Mascarel, I., MacGrogan, G., Picot, V., Dougazz, A., & Mathoulin-Pelissier, S. (2006). Results of a long term follow-up study of 115 patients with flat epithelial atypia. Laboratory investigation, 86(Suppl), 25A.
Del Mastro, L., Boni, L., Michelotti, A., & et al. (2011). Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA, 306(3), 269-276. https://doi.org/10.1001/jama.2011.991
Del Mastro, L., Bruzzi, P., Nicolo, G., Cavazzini, G., Contu, A., D'Amico, M., . . . Venturini, M. (2005). HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. British Journal of Cancer, 93(1), 7-14. https://doi.org/10.1038/sj.bjc.6602660
Del Mastro, L., Ceppi, M., Poggio, F., Bighin, C., Peccatori, F., Demeestere, I., . . . Bruzzi, P. (2014). Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 40(5), 675-683. https://doi.org/10.1016/j.ctrv.2013.12.001
Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., . . . Cognetti, F. (2015). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet, 385(9980), 1863-1872. https://doi.org/10.1016/s0140-6736(14)62048-1
Delanian, S., Lefaix, J. L., & Pradat, P. F. (2012). Radiation-induced neuropathy in cancer survivors. Radiotherapy and Oncology, 105(3), 273-282. https://doi.org/10.1016/j.radonc.2012.10.012
DeLong, M. R., Tandon, V. J., Bertrand, A. A., MacEachern, M., Goldberg, M., Salibian, A., . . . Wilkins, E. G. (2021). Review of Outcomes in Prepectoral Prosthetic Breast Reconstruction with and without Surgical Mesh Assistance. Plastic and reconstructive surgery, 147(2), 305-315. https://doi.org/10.1097/PRS.0000000000007586
Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., . . . Rolfo, C. (2022). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research, 28(7), 1302-1312. https://doi.org/10.1158/1078-0432.Ccr-21-3597
Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., . . . Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of clinical oncology, 36(23), 2433-2443. https://doi.org/10.1200/JCO.2018.78.8604
Deng, G., Vickers, A., Yeung, S., D'Andrea, G. M., Xiao, H., Heerdt, A. S., . . . Cassileth, B. (2007). Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. Journal of clinical oncology, 25(35), 5584-5590. https://doi.org/10.1200/JCO.2007.12.0774
Deshpande, N. A., Braun, I. M., & Meyer, F. L. (2015). Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: A systematic review. Cancer, 121(22), 3938-3947. https://doi.org/10.1002/cncr.29637
Diaz, R., Degnim, A. C., Boughey, J. C., Nassar, A., & Jakub, J. W. (2012). A positive intramammary lymph node does not mandate a complete axillary node dissection. American journal of surgery, 203(2), 151-155.
Dickler, M. N., Saura, C., Richards, D. A., Krop, I. E., Cervantes, A., Bedard, P. L., . . . Baselga, J. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical cancer research, 24(18), 4380-4387. https://doi.org/10.1158/1078-0432.CCR-18-0613
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., . . . Baselga, J. (2017). MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer. Clinical cancer research, 23(17), 5218-5224. https://doi.org/10.1158/1078-0432.Ccr-17-0754
Dieci, M. V., Griguolo, G., Bottosso, M., Tsvetkova, V., Giorgi, C. A., Vernaci, G., . . . Guarneri, V. (2021). Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ breast cancer, 7(1), 101. https://doi.org/10.1038/s41523-021-00308-7
Dijkema, I. M., Hofman, P., Raaijmakers, C. P., Lagendijk, J. J., Battermann, J. J., & Hillen, B. (2004). Loco-regional conformal radiotherapy of the breast: delineation of the regional lymph node clinical target volumes in treatment position. Radiotherapy and Oncology, 71(3), 287-295. https://doi.org/10.1016/j.radonc.2004.02.017
Domchek, S., & Kaunitz, A. M. (2016). Use of systemic hormone therapy in BRCA mutation carriers. Menopause, 23(9), 1026-1027. https://doi.org/10.1097/GME.0000000000000724
Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., . . . Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975. https://doi.org/10.1001/jama.2010.1237
Donegan, W. L., Perez-Mesa, C. M., & Watson, F. R. (1966). A biostatistical study of locally recurrent breast carcinoma. Surgery, gynecology & obstetrics, 122(3), 529-540.
Donker, M., Litière, S., Werutsky, G., Julien, J. P., Fentiman, I. S., Agresti, R., . . . Bijker, N. (2013). Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. Journal of clinical oncology, 31(32), 4054-4059. https://doi.org/10.1200/jco.2013.49.5077
Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., . . . Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-1352. https://doi.org/10.1016/s0140-6736(15)61074-1
Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., . . . Cuzick, J. (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Journal of clinical oncology, 31(22), 2783-2790. https://doi.org/10.1200/jco.2012.46.1558
Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thurlimann, B., . . . Cuzick, J. (2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. Journal of clinical oncology, 36(19), 1941-1948. https://doi.org/10.1200/jco.2017.76.4258
Duane, F., Aznar, M. C., Bartlett, F., Cutter, D. J., Darby, S. C., Jagsi, R., . . . Taylor, C. W. (2017). A cardiac contouring atlas for radiotherapy. Radiotherapy and Oncology, 122(3), 416-422. https://doi.org/10.1016/j.radonc.2017.01.008
Dupont, W. D., & Page, D. L. (1985). Risk factors for breast cancer in women with proliferative breast disease. The New England journal of medicine, 312(3), 146-151. https://doi.org/10.1056/NEJM198501173120303
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., Howe, D., Higgins, H. B., . . . Investigators, P. T. (2018). PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Journal of Clinical Oncology, 36(15 suppl), 506. https://doi.org/10.1200/JCO.2018.36.15_suppl.506
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365(9472), 1687-1717.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 393(10179), 1440-1452. https://doi.org/10.1016/s0140-6736(18)33137-4
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet. Oncology, 23(3), 382-392. https://doi.org/10.1016/s1470-2045(21)00758-0
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., . . . Darby, S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute. Monographs, 2010(41), 162-177. https://doi.org/10.1093/jncimonographs/lgq039
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet. Oncology, 22(8), 1139-1150. https://doi.org/10.1016/s1470-2045(21)00288-6
Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., . . . Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England journal of medicine, 372(23), 2243-2257. https://doi.org/10.1056/NEJMsr1501341
Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Röhl, F. W., . . . Costa, S. D. (2013). Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast cancer research and treatment, 137(2), 465-470. https://doi.org/10.1007/s10549-012-2355-3
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., . . . Coleman, R. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of oncology, 21(11), 2188-2194. https://doi.org/10.1093/annonc/mdq217
Eikesdal, H. P., Løes, S., & Herlofson, B. B. (2014). Tannhelse ved bruk av bisfosfonater mot brystkreft. Tidsskrift for den norske legeforening, 134(15), 1451. https://doi.org/10.4045/tidsskr.14.0717
Eisen, A., Somerfield, M. R., Accordino, M. K., Blanchette, P. S., Clemons, M. J., Dhesy-Thind, S., . . . Van Poznak, C. H. (2022). Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of clinical oncology, 40(7), 787-800. https://doi.org/10.1200/jco.21.02647
Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M. B., Knoop, A. S., Højris, I., . . . Mouridsen, H. T. (2017). Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. Journal of clinical oncology, 35(23), 2639-2646. https://doi.org/10.1200/jco.2017.72.3494
Elgindy, E., Sibai, H., Abdelghani, A., & Mostafa, M. (2015). Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. Obstetrics and gynecology, 126(1), 187-195. https://doi.org/10.1097/aog.0000000000000905
Elkins, G., Marcus, J., Stearns, V., & Hasan, R. M. (2007). Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology, 16(5), 487-492. https://doi.org/10.1002/pon.1096
Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., . . . Siegel, B. A. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA, 302(7), 774-780. https://doi.org/10.1001/jama.2009.1204
Elshof, L. E., Schmidt, M. K., Rutgers, E. J. T., van Leeuwen, F. E., Wesseling, J., & Schaapveld, M. (2018). Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of surgery, 267(5), 952-958. https://doi.org/10.1097/sla.0000000000002239
Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., . . . Schmid, P. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of oncology, 32(8), 983-993. https://doi.org/10.1016/j.annonc.2021.05.355
Eniu, A., Palmieri, F. M., & Perez, E. A. (2005). Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist, 10(9), 665-685. https://doi.org/10.1634/theoncologist.10-9-665
Eriksen, E. F., Moen, M. H., & Iversen, O. E. (2018). Østrogener i menopausen – på tide å endre anbefalingene? Tidsskrift for den norske legeforening, 138(6). https://doi.org/10.4045/tidsskr.17.1059
Esposito, N. N. (2012). Fibroepitelial lesions. I: D. J. Dabbs (red.), Breast pathology (s. 239-251). Philadelphia, PA: Elsevier (Saunders).
Esteva, F. J., Valero, V., Pusztai, L., Boehnke-Michaud, L., Buzdar, A. U., & Hortobagyi, G. N. (2001). Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist, 6(2), 133-146. https://doi.org/10.1634/theoncologist.6-2-133
Evans, D. G., Baildam, A. D., Anderson, E., Brain, A., Shenton, A., Vasen, H. F., . . . Howell, A. (2009). Risk reducing mastectomy: outcomes in 10 European centres. Journal of medical genetics, 46(4), 254-258. https://doi.org/10.1136/jmg.2008.062232
Evans, D. G., Kesavan, N., Lim, Y., Gadde, S., Hurley, E., Massat, N. J., . . . Duffy, S. W. (2014). MRI breast screening in high-risk women: cancer detection and survival analysis. Breast cancer research and treatment, 145(3), 663-672. https://doi.org/10.1007/s10549-014-2931-9
Falstie-Jensen, A. M., Esen, B., Kjærsgaard, A., Lorenzen, E. L., Jensen, J. D., Reinertsen, K. V., . . . Cronin-Fenton, D. P. (2020). Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study. Breast Cancer Research, 22(1), 106. https://doi.org/10.1186/s13058-020-01337-z
Faneyte, I. F., Rutgers, E. J., & Zoetmulder, F. A. (1997). Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer, 80(5), 886-891.
Farshid, G., & Buckley, E. (2019). Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast cancer research and treatment, 174(1), 165-177. https://doi.org/10.1007/s10549-018-5040-3
Feliciano, Y., Mamtani, A., Morrow, M., Stempel, M. M., Patil, S., & Jochelson, M. S. (2017). Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised? Annals of surgical oncology, 24(6), 1492-1498. https://doi.org/10.1245/s10434-016-5741-y
Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., & Nowak, A. K. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane database of systematic reviews, (4), CD004421. https://doi.org/10.1002/14651858.CD004421.pub2
Fertsch, S., Hagouan, M., Munder, B., Schulz, T., Abu-Ghazaleh, A., Schaberick, J., . . . Thamm, O. C. (2017). Increased risk of recurrence associated with certain risk factors in breast cancer patients after DIEP-flap reconstruction and lipofilling-a matched cohort study with 200 patients. Gland surgery, 6(4), 315-323. https://doi.org/10.21037/gs.2017.03.11
Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stoger, H., Jakesz, R., . . . Gnant, M. (2014). The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clinical cancer research, 20(5), 1298-1305. https://doi.org/10.1158/1078-0432.ccr-13-1845
Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., . . . Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of clinical oncology, 32(15), 1547-1553. https://doi.org/10.1200/JCO.2013.53.2820
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet. Oncology, 16(1), 25-35. https://doi.org/10.1016/s1470-2045(14)71159-3
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2014). Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 74(19 Suppl), CT101. https://doi.org/10.1158/1538-7445.AM2014-CT101
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., . . . Slamon, D. J. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. The New England journal of medicine, 375(20), 1925-1936. https://doi.org/10.1056/NEJMoa1607303
Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., . . . Slamon, D. J. (2022). Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Journal of Clinical Oncology, 40(17_suppl), LBA1003. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., . . . Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England journal of medicine, 347(16), 1233-1241. https://doi.org/10.1056/NEJMoa022152
Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., . . . Kavanah, M. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. Journal of clinical oncology, 16(2), 441-452. https://doi.org/10.1200/jco.1998.16.2.441
Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in oncology, 28(4), 400-418. https://doi.org/10.1016/s0093-7754(01)90133-2
Fisher, B., Ravdin, R. G., Ausman, R. K., Slack, N. H., Moore, G. E., & Noer, R. J. (1968). Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Annals of surgery, 168(3), 337-356. https://doi.org/10.1097/00000658-196809000-00004
Flemming, J., Madarnas, Y., & Franek, J. A. (2009). Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. Breast cancer research and treatment, 115(2), 255-268. https://doi.org/10.1007/s10549-008-0137-8
Fontein, D. B., van de Water, W., Mieog, J. S., Liefers, G. J., & Van de Velde, C. J. (2013). Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. European journal of surgical oncology, 39(5), 417-424.
Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., & Baum, M. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet. Oncology, 9(1), 45-53.
Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). (2000). FOR-2000-12-01-1208.
Forsythe, A., Zhang, W., Phillip Strauss, U., Fellous, M., Korei, M., & Keating, K. (2020). A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Therapeutic advances in medical oncology, 12, 1758835920975613. https://doi.org/10.1177/1758835920975613
Fountzilas, G., Athanassiades, A., Giannakakis, T., Briasoulis, E., Bafaloukos, D., Kalogera-Fountzila, A., . . . Skarlos, D. (1997). A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of oncology, 8(12), 1213-1220. https://doi.org/10.1023/a:1008270307264
Francis, P., Crown, J., Di, L. A., Buyse, M., Balil, A., Andersson, M., . . . Piccart-Gebhart, M. (2008). Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. Journal of the National Cancer Institute, 100(2), 121-133. https://doi.org/10.1093/jnci/djm287
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Lang, I., . . . Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. The New England journal of medicine, 379(2), 122-137. https://doi.org/10.1056/NEJMoa1803164
Francis, P. A., Regan, M. M., Fleming, G. F., Lang, I., Ciruelos, E., Bellet, M., . . . Gelber, R. D. (2015). Adjuvant ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 372(5), 436-446. https://doi.org/10.1056/NEJMoa1412379
Franzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., . . . Lambertini, M. (2021). Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. The Lancet. Oncology, 22(7), e303-e313. https://doi.org/10.1016/s1470-2045(20)30666-5
Frebourg, T., Bajalica Lagercrantz, S., Oliveira, C., Magenheim, R., & Evans, D. G. (2020). Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. European journal of human genetics : EJHG, 28(10), 1379-1386. https://doi.org/10.1038/s41431-020-0638-4
Frederick, M. J., Lin, A. M., Neuman, R., Smith, B. L., Austen, W. G., Jr., & Colwell, A. S. (2015). Nipple-sparing mastectomy in patients with previous breast surgery: comparative analysis of 775 immediate breast reconstructions. Plastic and reconstructive surgery, 135(6), 954e-962e. https://doi.org/10.1097/PRS.0000000000001283
Frey, J. D., Salibian, A. A., Choi, M., & Karp, N. S. (2020). Putting Together the Pieces: Development and Validation of a Risk-Assessment Model for Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 145(2), 273e-283e. https://doi.org/10.1097/PRS.0000000000006443
Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., . . . Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. Journal of clinical oncology, 34(25), 2961-2968. https://doi.org/10.1200/JCO.2016.67.3061
Friedl, T. W. P., Fehm, T., Müller, V., Lichtenegger, W., Blohmer, J., Lorenz, R., . . . Rack, B. (2021). Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA oncology, 7(8), 1149-1157. https://doi.org/10.1001/jamaoncol.2021.1854
Friedrich, M. (1998). MRI of the breast: state of the art. European radiology, 8(5), 707-725. https://doi.org/10.1007/s003300050463
Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., . . . Fergusson, D. (2013). Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS ONE, 8(11), e81968. https://doi.org/10.1371/journal.pone.0081968
Froud, P. J., Mates, D., Jackson, J. S., Phillips, N., Andersen, S., Jackson, S. M., . . . Olivotto, I. A. (2000). Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence. International journal of radiation oncology, biology, physics, 46(2), 363-372. https://doi.org/10.1016/S0360-3016(99)00412-5
Furet, E., Peurien, D., Fournier-Bidoz, N., Servois, V., Reyal, F., Fourquet, A., . . . Kirova, Y. M. (2014). Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost? European journal of surgical oncology, 40(7), 830-834. https://doi.org/10.1016/j.ejso.2014.03.009
Gale, K. L., Rakha, E. A., Ball, G., Tan, V. K., McCulley, S. J., & Macmillan, R. D. (2015). A case-controlled study of the oncologic safety of fat grafting. Plastic and reconstructive surgery, 135(5), 1263-1275. https://doi.org/10.1097/PRS.0000000000001151
Galimberti, V., Botteri, E., Chifu, C., Gentilini, O., Luini, A., Intra, M., . . . Veronesi, U. (2012). Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast cancer research and treatment, 131(3), 819-825.
Gao, J. J., Cheng, J., Prowell, T. M., Bloomquist, E., Tang, S., Wedam, S. B., . . . Amiri-Kordestani, L. (2021). Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. The Lancet. Oncology, 22(11), 1573-1581. https://doi.org/10.1016/s1470-2045(21)00472-1
Garreffa, E., Hughes-Davies, L., Russell, S., Lightowlers, S., & Agrawal, A. (2020). Definition of Tumor Bed Boost in Oncoplastic Breast Surgery: An Understanding and Approach. Clinical breast cancer, S1526-8209(20)30059-8 [epub ahead of print]. https://doi.org/10.1016/j.clbc.2020.03.003
Gasparini, G., Gion, M., Mariani, L., Papaldo, P., Crivellari, D., Filippelli, G., . . . Amadori, D. (2007). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast cancer research and treatment, 101(3), 355-365. https://doi.org/10.1007/s10549-006-9306-9
Gentile, P., Bernini, M., Orzalesi, L., Sordi, S., Meattini, I., Lessi, F., . . . Calabrese, C. (2021). Titanium-coated polypropylene mesh as innovative bioactive material in conservatives mastectomies and pre-pectoral breast reconstruction. Bioactive Materials, 6(12), 4640-4653. https://doi.org/10.1016/j.bioactmat.2021.05.002
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., . . . Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 355(26), 2733-2743. https://doi.org/10.1056/NEJMoa064320
Geyer, C. E., Jr., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., . . . Tutt, A. N. J. (2022a). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of oncology, 33(12), 1250-1268. https://doi.org/10.1016/j.annonc.2022.09.159
Geyer, C. E., Sikov, W. M., Huober, J., Rugo, H. S., Wolmark, N., O'Shaughnessy, J., . . . Loibl, S. (2022b). Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of oncology, 33(4), 384-394. https://doi.org/10.1016/j.annonc.2022.01.009
Ghersi, D., Wilcken, N., Simes, J., & Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer. Cochrane database of systematic reviews, (2), CD003366.
Giannakeas, V., Sopik, V., & Narod, S. A. (2020). Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA network open, 3(9), e2017124. https://doi.org/10.1001/jamanetworkopen.2020.17124
Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., . . . Tusquets, I. (2018). Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA oncology, 4(3), 302-308. https://doi.org/10.1001/jamaoncol.2017.4612
Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., . . . Valagussa, P. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 17(6), 791-800. https://doi.org/10.1016/s1470-2045(16)00163-7
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane database of systematic reviews, (4), CD003370. https://doi.org/10.1002/14651858.CD003370.pub3
Gilliland, M. D., Barton, R. M., & Copeland, E. M., 3rd. (1983). The implications of local recurrence of breast cancer as the first site of therapeutic failure. Annals of surgery, 197(3), 284-287.
Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., . . . Arteaga, C. L. (2017). Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine, 9(402), eaai7993. https://doi.org/10.1126/scitranslmed.aai7993
Giordano, S. H., Kuo, Y. F., Freeman, J. L., Buchholz, T. A., Hortobagyi, G. N., & Goodwin, J. S. (2005). Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute, 97(6), 419-424. https://doi.org/10.1093/jnci/dji067
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., . . . Winer, E. P. (2014). Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology, 32(19), 2078-2099. https://doi.org/10.1200/jco.2013.54.0948
Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., . . . Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 305(6), 569-575.
Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., . . . Ballman, K. (2010). Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of surgery, 252(3), 426-432. https://doi.org/10.1097/SLA.0b013e3181f08f32
Glaser, R., & Dimitrakakis, C. (2015). Testosterone and breast cancer prevention. Maturitas, 82(3), 291-295. https://doi.org/10.1016/j.maturitas.2015.06.002
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., . . . Harbeck, N. (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. Journal of clinical oncology, 34(20), 2341-2349. https://doi.org/10.1200/jco.2015.63.5383
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., . . . Mayer, E. L. (2022a). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of clinical oncology, 40(3), 282-293. https://doi.org/10.1200/jco.21.02554
Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil-Ressler, S., Balic, M., . . . Greil, R. (2021). Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. The New England journal of medicine, 385(5), 395-405. https://doi.org/10.1056/NEJMoa2104162
Gnant, M., Frantal, S., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., . . . Singer, C. F. (2022b). Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. Journal of Clinical Oncology, 40(16_suppl), 507. https://doi.org/10.1200/JCO.2022.40.16_suppl.507
Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Stoeger, H., Dubsky, P., Jakesz, R., . . . Greil, R. (2011a). Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. (Abstract [S1-2] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-2
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., . . . Marth, C. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 360(7), 679-691. https://doi.org/10.1056/NEJMoa0806285
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., . . . Greil, R. (2011b). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. The Lancet. Oncology, 12(7), 631-641. https://doi.org/10.1016/S1470-2045(11)70122-X
Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., . . . Cuzick, J. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Annals of oncology, 26(8), 1685-1691. https://doi.org/10.1093/annonc/mdv215
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., . . . Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast cancer research and treatment, 101(1), 113-121. https://doi.org/10.1007/s10549-006-9428-0
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., . . . Di Leo, A. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of clinical oncology, 35(32), 3638-3646. https://doi.org/10.1200/jco.2017.75.6155
Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B., . . . Chenevix-Trench, G. (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Research, 13(4), R73. https://doi.org/10.1186/bcr2919
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., . . . Baselga, J. (2013a). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/s0140-6736(13)61094-6
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of oncology, 16(10), 1569-1583. https://doi.org/10.1093/annonc/mdi326
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of oncology, 20(8), 1319-1329. https://doi.org/10.1093/annonc/mdp322
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B., & Senn, H. J. (2013b). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology, 24(9), 2206-2223. https://doi.org/10.1093/annonc/mdt303
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B., & Senn, H. J. (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology, 22(8), 1736-1747. https://doi.org/10.1093/annonc/mdr304
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of oncology, 18(7), 1133-1144. https://doi.org/10.1093/annonc/mdm271
Gompel, A., Sirmoachkova, M., Lombet, A., Thevenin, D., Mimoun, M., & Poitout, P. (1997). The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecological Endocrinology, 11(Suppl 1), 77-79.
Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., . . . Arver, B. (2014). Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World journal of surgery, 38(7), 1685-1693. https://doi.org/10.1007/s00268-014-2605-0
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Livingston, R. B., . . . Tu, D. (2013). Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of oncology, 24(2), 355-361. https://doi.org/10.1093/annonc/mds330
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., . . . Parulekar, W. R. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. The New England journal of medicine, 375(3), 209-219. https://doi.org/10.1056/NEJMoa1604700
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009). Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Journal of clinical oncology, 27(22), 3611-3619. https://doi.org/10.1200/Jco.2008.18.5397
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., . . . O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of clinical oncology, 23(31), 7794-7803. https://doi.org/10.1200/jco.2005.04.937
Gravina, P. R., Pettit, R. W., Davis, M. J., Winocour, S. J., & Selber, J. C. (2019). Evidence for the Use of Acellular Dermal Matrix in Implant-Based Breast Reconstruction. Seminars in plastic surgery, 33(4), 229-235. https://doi.org/10.1055/s-0039-1696986
Gray, R., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., . . . al., e. (2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO Annual meeting, abstract.no 05.
Gregory, W., Marshall, H., Bell, R., Cameron, D. A., & Coleman, R. E. (2012). Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. Journal of clinical oncology, 30(15 Supplement), 513.
Griepsma, M., de Roy van Zuidewijn, D. B., Grond, A. J., Siesling, S., Groen, H., & de Bock, G. H. (2014). Residual breast tissue after mastectomy: how often and where is it located? Annals of surgical oncology, 21(4), 1260-1266. https://doi.org/10.1245/s10434-013-3383-x
Grogan, M., Tabar, L., Chua, B., Chen, H. H., & Boyages, J. (2001). Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. The British journal of surgery, 88(11), 1513-1518. https://doi.org/10.1046/j.0007-1323.2001.01902.x
Gundersen, S., Hannisdal, E., Lundgren, S., & Wist, E. (1994). Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group. European journal of cancer, 30A(12), 1775-1778. https://doi.org/Doi 10.1016/0959-8049(94)00213-O
Gundersen, S., Kvinnsland, S., Klepp, O., Kvaloy, S., Lund, E., & Host, H. (1986). Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. European journal of cancer & clinical oncology, 22(12), 1431-1434. https://doi.org/10.1016/0277-5379(86)90075-1
Gøtzsche, P. C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane database of systematic reviews, (1), CD001877.
Habberstad, R., Frøseth, T. C. S., Aass, N., Bjerkeset, E., Abramova, T., Garcia-Alonso, E., . . . Klepstad, P. (2021). Clinical Predictors for Analgesic Response to Radiotherapy in Patients with Painful Bone Metastases. Journal of pain and symptom management, 62(4), 681-690. https://doi.org/10.1016/j.jpainsymman.2021.03.022
Hagen, A. I., Tretli, S., Maehle, L., Apold, J., Veda, N., & Moller, P. (2009). Survival in Norwegian BRCA1 mutation carriers with breast cancer. Hereditary cancer in clinical practice, 7(1), 7. https://doi.org/10.1186/1897-4287-7-7
Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., & Fineberg, B. (1990). Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. International journal of radiation oncology, biology, physics, 19(4), 851-858. https://doi.org/10.1016/0360-3016(90)90004-4
Hamdi, M., Spano, A., Van Landuyt, K., D'Herde, K., Blondeel, P., & Monstrey, S. (2008). The lateral intercostal artery perforators: anatomical study and clinical application in breast surgery. Plastic and reconstructive surgery, 121(2), 389-396. https://doi.org/10.1097/01.prs.0000298317.65296.cf
Hancock, S. L., Cox, R. S., & McDougall, I. R. (1991). Thyroid diseases after treatment of Hodgkin's disease. The New England journal of medicine, 325(9), 599-605. https://doi.org/10.1056/NEJM199108293250902
Hannoun-Levi, J. M., Resch, A., Gal, J., Kauer-Dorner, D., Strnad, V., Niehoff, P., . . . Polgár, C. (2013). Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiotherapy and Oncology, 108(2), 226-231. https://doi.org/10.1016/j.radonc.2013.03.026
Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., & Hortobagyi, G. N. (2006). Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. Journal of clinical oncology, 24(13), 2113-2122.
Harbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., . . . O'Shaughnessy, J. (2021). Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of oncology, 32(12), 1571-1581. https://doi.org/10.1016/j.annonc.2021.09.015
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., . . . Winer, E. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94(1), 25-36. https://doi.org/10.1002/cncr.10201
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., . . . Hayes, D. F. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology, 34(10), 1134-1150. https://doi.org/10.1200/jco.2015.65.2289
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., . . . Jenkins, R. B. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute, 93(21), 1633-1637. https://doi.org/10.1093/jnci/93.21.1633
Harvey, J. A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., . . . Haffty, B. G. (2016). ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology : JACR, 13(11s), e31-e42. https://doi.org/10.1016/j.jacr.2016.09.022
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., . . . Yarnold, J. R. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. The Lancet. Oncology, 14(11), 1086-1094. https://doi.org/10.1016/S1470-2045(13)70386-3
Hayes, D. F., & Rae, J. M. (2020). Pharmacogenomics and Endocrine Therapy in Breast Cancer. Journal of clinical oncology, 38(6), 525-528. https://doi.org/10.1200/JCO.19.03119
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., . . . Berry, D. A. (2007). HER2 and response to paclitaxel in node-positive breast cancer. The New England journal of medicine, 357(15), 1496-1506. https://doi.org/10.1056/NEJMoa071167
Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., & Wilson, K. S. (2000). Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. International journal of radiation oncology, biology, physics, 46(2), 355-362. https://doi.org/Doi 10.1016/S0360-3016(99)00428-9
He, W., Grassmann, F., Eriksson, M., Eliasson, E., Margolin, S., Thoren, L., . . . Czene, K. (2020). CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. Journal of clinical oncology, 38(6), 548-557. https://doi.org/10.1200/JCO.19.01535
Heemskerk-Gerritsen, B. A., Brekelmans, C. T., Menke-Pluymers, M. B., van Geel, A. N., Tilanus-Linthorst, M. M., Bartels, C. C., . . . Seynaeve, C. (2007). Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Annals of surgical oncology, 14(12), 3335-3344. https://doi.org/10.1245/s10434-007-9449-x
Heemskerk-Gerritsen, B. A., Menke-Pluijmers, M. B., Jager, A., Tilanus-Linthorst, M. M., Koppert, L. B., Obdeijn, I. M., . . . Hooning, M. J. (2013). Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Annals of oncology, 24(8), 2029-2035. https://doi.org/10.1093/annonc/mdt134
Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., . . . Seynaeve, C. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International Journal of Cancer, 136(3), 668-677. https://doi.org/10.1002/ijc.29032
Helse- og omsorgsdepartementet. (2006). Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf
Helse- og omsorgsdepartementet. (2013). Sammen – mot kreft: nasjonal kreftstrategi 2013–2017. Oslo: Helse- og omsorgsdepartementet.
Helse- og omsorgsdepartementet. (2018). Leve med kreft: nasjonal kreftstrategi 2018–2022. Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/contentassets/266bf1eec38940888a589ec86d79da20/regjeringens_kreftstrategi_180418.pdf
Helsedirektoratet. (2016). Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Oslo: Helsedirektoratet. Hentet fra http://helsebiblioteket.no/retningslinjer/gynekologisk-kreft/forord
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016). The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clinical cancer research, 22(1), 259-267. https://doi.org/10.1158/1078-0432.CCR-14-3212
Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., . . . Romestaing, P. (2013). Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. International journal of radiation oncology, biology, physics, 86(5), 860-866. https://doi.org/10.1016/j.ijrobp.2013.03.021
Henry, N. L., Unger, J. M., Schott, A. F., Fehrenbacher, L., Flynn, P. J., Prow, D. M., . . . Wade, J. L., 3rd. (2018). Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology, 36(4), 326-332. https://doi.org/10.1200/jco.2017.74.6651
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W. Y., . . . Neugut, A. I. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of clinical oncology, 28(27), 4120-4128. https://doi.org/10.1200/jco.2009.25.9655
Hickey, B. E., Francis, D., & Lehman, M. H. (2006). Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane database of systematic reviews, (4), CD005212. https://doi.org/10.1002/14651858.CD005212.pub2
Hickey, M., Saunders, C., Partridge, A., Santoro, N., Joffe, H., & Stearns, V. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of oncology, 19(10), 1669-1680. https://doi.org/10.1093/annonc/mdn353
Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., . . . Pfister, D. G. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. Journal of clinical oncology, 18(6), 1378-1391. https://doi.org/10.1200/JCO.2000.18.6.1378
Himelstein, A. L., Qin, R., Novotny, P. J., Seisler, D. K., Khatcheressian, J. L., Roberts, J. D., & Grubbs, S. S. (2015). A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of clinical oncology, 33(15 suppl), abstract 9501.
Hoberg-Vetti, H., Bjorvatn, C., Fiane, B. E., Aas, T., Woie, K., Espelid, H., . . . Hoogerbrugge, N. (2016). BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European journal of human genetics : EJHG, 24(6), 881-888. https://doi.org/10.1038/ejhg.2015.196
Hofvind, S., Ursin, G., Tretli, S., Sebuødegård, S., & Møller, B. (2013). Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer, 119(17), 3106-3112. https://doi.org/10.1002/cncr.28174
Holmberg, L., Garmo, H., Granstrand, B., Ringberg, A., Arnesson, L. G., Sandelin, K., . . . Emdin, S. (2008a). Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. Journal of clinical oncology, 26(8), 1247-1252. https://doi.org/10.1200/jco.2007.12.7969
Holmberg, L., Iversen, O. E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., . . . Maenpaa, J. (2008b). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute, 100(7), 475-482. https://doi.org/10.1093/jnci/djn058
Hoogstraten, B., Gad-el-Mawla, N., Maloney, T. R., Fletcher, W. S., Vaughn, C. B., Tranum, B. L., . . . Foulkes, M. (1984). Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer, 54(10), 2248-2256. https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co;2-d
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Hart, L., . . . O'Shaughnessy, J. (2022). Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England journal of medicine, 386(10), 942-950. https://doi.org/10.1056/NEJMoa2114663
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England journal of medicine, 375(18), 1738-1748. https://doi.org/10.1056/NEJMoa1609709
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology, 29(7), 1541-1547. https://doi.org/10.1093/annonc/mdy155
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., . . . Knight, R. D. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. The New England journal of medicine, 335(24), 1785-1791. https://doi.org/10.1056/NEJM199612123352401
Houghton, J., George, W. D., Cuzick, J., Duggan, C., Fentiman, I. S., & Spittle, M. (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 362(9378), 95-102. https://doi.org/10.1016/s0140-6736(03)13859-7
Houssami, N., Macaskill, P., Marinovich, M. L., Dixon, J. M., Irwig, L., Brennan, M. E., & Solin, L. J. (2010). Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. European journal of cancer, 46(18), 3219-3232. https://doi.org/10.1016/j.ejca.2010.07.043
Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012). Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. European journal of cancer, 48(18), 3342-3354. https://doi.org/10.1016/j.ejca.2012.05.023
Houssami, N., Turner, R., & Morrow, M. (2013). Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Annals of surgery, 257(2), 249-255. https://doi.org/10.1097/SLA.0b013e31827a8d17
Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., . . . Couch, F. J. (2021). A Population-Based Study of Genes Previously Implicated in Breast Cancer. The New England journal of medicine, 384(5), 440-451. https://doi.org/10.1056/NEJMoa2005936
Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Buzdar, A. U., . . . Buchholz, T. A. (2004). Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. Journal of clinical oncology, 22(23), 4691-4699. https://doi.org/10.1200/JCO.2004.11.129
Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O., Perou, C. M., Dumontet, C., . . . Vogel, C. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of clinical oncology, 27(8), 1168-1176.
Hughes, R. T., Masters, A. H., McTyre, E. R., Farris, M. K., Chung, C., Page, B. R., . . . Chan, M. D. (2019). Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International journal of radiation oncology, biology, physics, 104(5), 1091-1098. https://doi.org/10.1016/j.ijrobp.2019.03.052
Hunt, K. K., Yi, M., Mittendorf, E. A., Guerrero, C., Babiera, G. V., Bedrosian, I., . . . Meric-Bernstam, F. (2009). Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Annals of surgery, 250(4), 558-566. https://doi.org/10.1097/SLA.0b013e3181b8fd5e
Hurvitz, S., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., . . . Cortés, J. (2022). Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Research, 82(4 Suppl), GS3-01. https://doi.org/10.1158/1538-7445.Sabcs21-gs3-01
Højris, I., Overgaard, M., Christensen, J. J., & Overgaard, J. (1999). Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet, 354(9188), 1425-1430.
IARC. (2002). Breast cancer screening (IARC Handbooks of cancer prevention volume 7). Lyon: IARC Press.
Ignatov, A., Eggemann, H., Burger, E., & Ignatov, T. (2018). Patterns of breast cancer relapse in accordance to biological subtype. Journal of Cancer Research and Clinical Oncology, 144(7), 1347-1355. https://doi.org/10.1007/s00432-018-2644-2
Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., . . . Tripathy, D. (2019). Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. The New England journal of medicine, 381(4), 307-316. https://doi.org/10.1056/NEJMoa1903765
Independent, U. K. P. o. B. C. S. (2012). The benefits and harms of breast cancer screening: an independent review. Lancet, 380(9855), 1778-1786. https://doi.org/10.1016/S0140-6736(12)61611-0
Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., . . . Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European journal of cancer, 46(12), 2275-2284. https://doi.org/10.1016/j.ejca.2010.04.018
Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., . . . Wolfgang, J. (2005). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366(9484), 455-462. https://doi.org/10.1016/S0140-6736(05)67059-6
Jensen, A. K., Kristensen, S. G., Macklon, K. T., Jeppesen, J. V., Fedder, J., Ernst, E., & Andersen, C. Y. (2015). Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Human reproduction, 30(12), 2838-2845. https://doi.org/10.1093/humrep/dev230
Jereczek-Fossa, B. A., Alterio, D., Jassem, J., Gibelli, B., Tradati, N., & Orecchia, R. (2004). Radiotherapy-induced thyroid disorders. Cancer Treatment Reviews, 30(4), 369-384. https://doi.org/10.1016/j.ctrv.2003.12.003
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., . . . Kellokumpu-Lehtinen, P. L. (2009). Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of clinical oncology, 27(34), 5685-5692. https://doi.org/10.1200/jco.2008.21.4577
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., . . . Lindman, H. (2018). Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA oncology, 4(9), 1199-1206. https://doi.org/10.1001/jamaoncol.2018.1380
Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., . . . Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England journal of medicine, 354(8), 809-820. https://doi.org/10.1056/NEJMoa053028
Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Kokko, R., . . . Lindman, H. (2012). Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of clinical oncology, 30(1), 11-18. https://doi.org/10.1200/jco.2011.35.4639
Joensuu, H., & Viikari, J. (1986). Thyroid function after postoperative radiation therapy in patients with breast cancer. Acta radiologica. Oncology, 25(3), 167-170. https://doi.org/10.3109/02841868609136397
Johansen, K., Lønning, P. E., Naume, B., Norderhaug, I., Norum, J., Olsen, J. A., & Wist, E. (2006). Ny medikamentell behandling av brystkreft - adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft (Rapport fra Kunnskapssenteret nr 02-2006). Oslo: Kunnskapssenteret. Hentet fra https://www.fhi.no/publ/eldre/ny-medikamentell-behandling-av-brystkreft.--adjuvant-behandling-med-trastuz/
Johansson, S., Svensson, H., & Denekamp, J. (2002). Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. International journal of radiation oncology, biology, physics, 52(5), 1207-1219. https://doi.org/10.1016/s0360-3016(01)02743-2
Johnson, D. J. (2021). Discussion: MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 567-568. https://doi.org/10.1097/PRS.0000000000007691
Johnston, S., Pippen, J., Jr., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., . . . Pegram, M. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of clinical oncology, 27(33), 5538-5546. https://doi.org/10.1200/Jco.2009.23.3734
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., . . . Rastogi, P. (2020). Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of clinical oncology, 38(34), 3987-3998. https://doi.org/10.1200/jco.20.02514
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., . . . Asmar, L. (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of clinical oncology, 24(34), 5381-5387. https://doi.org/10.1200/jco.2006.06.5391
Kaidar-Person, O., Dahn, H. M., Nichol, A. M., Boersma, L. J., de Ruysscher, D., Meattini, I., . . . Offersen, B. V. (2021). A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiotherapy and Oncology, 164, 115-121. https://doi.org/10.1016/j.radonc.2021.09.012
Kaidar-Person, O., Oldenborg, S., & Poortmans, P. (2018). Re-irradiation and Hyperthermia in Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 30(2), 73-84. https://doi.org/10.1016/j.clon.2017.11.004
Kaidar-Person, O., Vrou Offersen, B., Hol, S., Arenas, M., Aristei, C., Bourgier, C., . . . Poortmans, P. (2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiotherapy and Oncology, 137, 159-166. https://doi.org/10.1016/j.radonc.2019.04.010
Kalinsky, K., Accordino, M. K., Chiuzan, C., Mundi, P. S., Trivedi, M. S., Novik, Y., . . . Hershman, D. L. (2022). A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Journal of Clinical Oncology, 40(17_suppl), LBA1004. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1004
Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., . . . Hortobagyi, G. N. (2021). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. The New England journal of medicine, 385(25), 2336-2347. https://doi.org/10.1056/NEJMoa2108873
Kamby, C., & Sengelov, L. (1997). Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast cancer research and treatment, 45(2), 181-192. https://doi.org/Doi 10.1023/A:1005845100512
Karlsson, P., Cole, B. F., Colleoni, M., Roncadin, M., Chua, B. H., Murray, E., . . . Gruber, G. (2011). Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. International journal of radiation oncology, biology, physics, 80(2), 398-402. https://doi.org/10.1016/j.ijrobp.2010.02.042
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., . . . Jones, A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of clinical oncology, 27(33), 5529-5537. https://doi.org/10.1200/JCO.2008.20.6847
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., . . . Cortes, J. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology, 33(6), 594-601. https://doi.org/10.1200/jco.2013.52.4892
Kaufmann, M., Karn, T., & Ruckhaberle, E. (2012). Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer. World J Surg., 36(7), 1480-1485. https://doi.org/10.1007/s00268-012-1424-4
Kelly, B. N., Faulkner, H. R., Smith, B. L., Korotkin, J. E., Lanahan, C. R., Brown, C., . . . Coopey, S. B. (2022). Nipple-Sparing Mastectomy versus Skin-Sparing Mastectomy: Does Saving the Nipple Impact Short- and Long-Term Patient Satisfaction? Annals of surgical oncology, 29(2), 1033-1040. https://doi.org/10.1245/s10434-021-10767-8
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010). Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ, 340, c693. https://doi.org/10.1136/bmj.c693
Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of oncology, 17(4), 584-587. https://doi.org/10.1093/annonc/mdj127
Kenemans, P., Bundred, N. J., Foidart, J. M., Kubista, E., von Schoultz, B., Sismondi, P., . . . Beckmann, M. W. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet. Oncology, 10(2), 135-146. https://doi.org/10.1016/S1470-2045(08)70341-3
Kerlikowske, K., Molinaro, A., Cha, I., Ljung, B. M., Ernster, V. L., Stewart, K., . . . Waldman, F. (2003). Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. Journal of the National Cancer Institute, 95(22), 1692-1702. https://doi.org/10.1093/jnci/djg097
Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., . . . Davidson, N. E. (2006). American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. Journal of clinical oncology, 24(31), 5091-5097. https://doi.org/10.1200/JCO.2006.08.8575
Kim, S. B., Dent, R., Im, S. A., Espie, M., Blau, S., Tan, A. R., . . . investigators, L. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3
Kim, T., Giuliano, A. E., & Lyman, G. H. (2006). Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 106(1), 4-16. https://doi.org/10.1002/cncr.21568
Kisqali. (4. mai 2020). Felleskatalogen [database]. Oslo: Felleskatalogen AS. Hentet 11. mai 2020, fra https://www.felleskatalogen.no/medisin/kisqali-novartis-642779
Klintman, M., Strand, C., Ahlin, C., Beglerbegovic, S., Fjällskog, M. L., Grabau, D., . . . Ferno, M. (2013). The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS ONE, 8(12), e81902. https://doi.org/10.1371/journal.pone.0081902
Ko, M. J., Park, D. A., Kim, S. H., Ko, E. S., Shin, K. H., Lim, W., . . . Chang, J. M. (2021). Accuracy of Digital Breast Tomosynthesis for Detecting Breast Cancer in the Diagnostic Setting: A Systematic Review and Meta-Analysis. Korean journal of radiology, 22(8), 1240-1252. https://doi.org/10.3348/kjr.2020.1227
Kollias, J., Murphy, C. A., Elston, C. W., Ellis, I. O., Robertson, J. F., & Blamey, R. W. (1999). The prognosis of small primary breast cancers. European journal of cancer, 35(6), 908-912. https://doi.org/10.1016/s0959-8049(99)00056-8
Kopans, D. B. (2007). Breast Imaging (3. utg.). Philadelphia Lippincott Williams and Wilkins.
Korde, L. A., Somerfield, M. R., Hershman, D. L., & Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline Expert Panel. (2022). Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology, 40(15), 1696-1698. https://doi.org/10.1200/jco.22.00503
Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T., & Aoki, Y. (1977). Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer, 39(4), 1403-1409. https://doi.org/10.1002/1097-0142(197704)39:4<1403::aid-cncr2820390408>3.0.co;2-8
Krastev, T., van Turnhout, A., Vriens, E., Smits, L., & van der Hulst, R. (2019). Long-term Follow-up of Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer Relapse in Patients With Breast Cancer. JAMA surgery, 154(1), 56-63. https://doi.org/10.1001/jamasurg.2018.3744
Krastev, T. K., Schop, S. J., Hommes, J., Piatkowski, A. A., Heuts, E. M., & van der Hulst, R. (2018). Meta-analysis of the oncological safety of autologous fat transfer after breast cancer. The British journal of surgery, 105(9), 1082-1097. https://doi.org/10.1002/bjs.10887
Kreftregisteret. (2018). Årsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Oslo: Kreftregisteret. Hentet fra https://www.kvalitetsregistre.no/sites/default/files/13_arsrapport_2017_brystkreft.pdf
Kronowitz, S. J., Mandujano, C. C., Liu, J., Kuerer, H. M., Smith, B., Garvey, P., . . . Valero, V. (2016). Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plastic and reconstructive surgery, 137(2), 385-393. https://doi.org/10.1097/01.prs.0000475741.32563.50
Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., . . . Stearns, V. (2017). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of clinical oncology, 35(24), 2838-2847. https://doi.org/10.1200/jco.2017.74.0472
Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., . . . Wildiers, H. (2014). Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 15(7), 689-699. https://doi.org/10.1016/s1470-2045(14)70178-0
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., . . . Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416. https://doi.org/10.1001/jama.2017.7112
Kucuk, O. (2017). Soy foods, isoflavones, and breast cancer. Cancer, 123(11), 1901-1903. https://doi.org/10.1002/cncr.30614
Kuo, S. H., Huang, C. S., Kuo, W. H., Cheng, A. L., Chang, K. J., & Chia-Hsien, C. J. (2008). Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. International journal of radiation oncology, biology, physics, 72(5), 1456-1464. https://doi.org/10.1016/j.ijrobp.2008.03.042
Kurata, K., Kubo, M., Kai, M., Mori, H., Kawaji, H., Kaneshiro, K., . . . Nakamura, M. (2020). Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 27(3), 490-498. https://doi.org/10.1007/s12282-019-01043-5
Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of clinical oncology, 28(2), 222-231. https://doi.org/10.1200/JCO.2009.22.7991
Lakhani, S. R., Schnitt, S., O'Malley, F., Van de Vijver, M. J., Simpson, P. T., & Palacios, J. (2019). Lobular neoplasia. I: WHO Classification of Tumours Editorial Board (red.), WHO classification of Tumours of the Breast, Volume 2 (5. utg., s. 71-74). Lyan: IARC.
Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F. A., Azim, H. A., Jr., Ugolini, D., . . . Del Mastro, L. (2015). Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annals of oncology, 26(12), 2408-2419. https://doi.org/10.1093/annonc/mdv374
Landercasper, J., Attai, D., Atisha, D., Beitsch, P., Bosserman, L., Boughey, J., . . . Cody, H., 3rd. (2015). Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Annals of surgical oncology, 22(10), 3174-3183. https://doi.org/10.1245/s10434-015-4759-x
Larsen, I. K. (2021). Cancer in Norway 2020: Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2020/cin-2020.pdf
Larsen, I. K. (red.). (2019). Cancer in Norway 2018: Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2018/cin2018.pdf
Larson, K. E., Grobmyer, S. R., & Valente, S. A. (2018). Evaluation of recurrence patterns and survival in modern series of young women with breast cancer. The breast journal, 24(5), 749-754. https://doi.org/10.1111/tbj.13041
Lawenda, B. D., Mondry, T. E., & Johnstone, P. A. (2009). Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin, 59(1), 8-24. https://doi.org/10.3322/caac.20001
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., . . . Diaz, L. A., Jr. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413. https://doi.org/10.1126/science.aan6733
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., . . . Diaz, L. A., Jr. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine, 372(26), 2509-2520. https://doi.org/10.1056/NEJMoa1500596
Lee, L. A., Silverstein, M. J., Chung, C. T., Macdonald, H., Sanghavi, P., Epstein, M., . . . Lagios, M. D. (2006). Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. American journal of surgery, 192(4), 416-419. https://doi.org/10.1016/j.amjsurg.2006.06.005
Lee, S. H., Lee, J., Park, J., Park, S. H., Lee, K. E., Lee, S. I., . . . Im, Y. H. (2004). Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Medical oncology, 21(3), 223-231. https://doi.org/10.1385/MO:21:3:223
Lehman, C. D., Lee, A. Y., & Lee, C. I. (2014). Imaging management of palpable breast abnormalities. AJR. American journal of roentgenology, 203(5), 1142-1153. https://doi.org/10.2214/ajr.14.12725
Leidenius, M. H., Krogerus, L. A., Toivonen, T. S., Leppanen, E. A., & von Smitten, K. A. (2006). The clinical value of parasternal sentinel node biopsy in breast cancer. Annals of surgical oncology, 13(3), 321-326. https://doi.org/10.1245/ASO.2006.02.022
Lende, T. H., Janssen, E. A., Gudlaugsson, E., Voorhorst, F., Smaaland, R., van Diest, P., . . . Baak, J. P. (2011). In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! Journal of clinical oncology, 29(7), 852-858. https://doi.org/10.1200/jco.2009.25.0407
Leon-Ferre, R. A., Novotny, P. J., Wolfe, E. G., Faubion, S. S., Ruddy, K. J., Flora, D., . . . Loprinzi, C. L. (2020). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI cancer spectrum, 4(1), pkz088. https://doi.org/10.1093/jncics/pkz088
Levernes, S., & Johannessen, D. C. (2003). Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering (Strålevern rapport 2003:12). Oslo: Statens strålevern. Hentet fra https://dsa.no/publikasjoner/stralevernrapport-12-2003-volum-og-doser-ved-stralebehandling/straalevernrapport-2003-12-volum-og-doser-ved-straalebehandling-definisjoner-retningslinjer-dokumentasjon-rapportering.pdf
Li, J., Yu, K., Pang, D., Wang, C., Jiang, J., Yang, S., . . . Shao, Z. (2020). Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. Journal of clinical oncology, 38(16), 1774-1784. https://doi.org/10.1200/jco.19.02474
Liang, S., Hallet, J., Simpson, J. S., Tricco, A. C., & Scheer, A. S. (2017). Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. J Geriatr Oncol, 8(2), 140-147. https://doi.org/10.1016/j.jgo.2016.12.003
Lind, P. A., Wennberg, B., Gagliardi, G., & Fornander, T. (2001). Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast cancer research and treatment, 68(3), 199-210. https://doi.org/10.1023/a:1012292019599
Litiere, S., Werutsky, G., Fentiman, I. S., Rutgers, E., Christiaens, M. R., Van Limbergen, E., . . . Bartelink, H. (2012). Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. The Lancet. Oncology, 13(4), 412-419. https://doi.org/10.1016/S1470-2045(12)70042-6
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K. H., Gonçalves, A., . . . Ettl, J. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of oncology, 31(11), 1526-1535. https://doi.org/10.1016/j.annonc.2020.08.2098
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., . . . Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England journal of medicine, 379(8), 753-763. https://doi.org/10.1056/NEJMoa1802905
Liu, Y., Malin, J. L., Diamant, A. L., Thind, A., & Maly, R. C. (2013). Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast cancer research and treatment, 137(3), 829-836. https://doi.org/10.1007/s10549-012-2387-8
Lluch, A., Barrios, C. H., Torrecillas, L., Ruiz-Borrego, M., Bines, J., Segalla, J., . . . Martín, M. (2020). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of clinical oncology, 38(3), 203-213. https://doi.org/10.1200/jco.19.00904
Loesch, D., Asmar, L., McIntyre, K., Doane, L., Monticelli, M., Paul, D., . . . O'Shaughnessy, J. A. (2008). Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clinical breast cancer, 8(2), 178-186. https://doi.org/10.3816/CBC.2008.n.019
Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006). Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. Journal of clinical oncology, 24(30), 4888-4894. https://doi.org/10.1200/JCO.2005.01.6089
Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., . . . Amant, F. (2012). Treatment of breast cancer during pregnancy: an observational study. The Lancet. Oncology, 13(9), 887-896. https://doi.org/10.1016/s1470-2045(12)70261-9
Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S. B., . . . von Minckwitz, G. (2021). Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. Journal of clinical oncology, 39(14), 1518-1530. https://doi.org/10.1200/jco.20.03639
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., . . . Geyer, C. E., Jr. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet. Oncology, 19(4), 497-509. https://doi.org/10.1016/s1470-2045(18)30111-6
Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., . . . Amant, F. (2015). Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA oncology, 1(8), 1145-1153. https://doi.org/10.1001/jamaoncol.2015.2413
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., . . . Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of oncology, 33(11), 1149-1158. https://doi.org/10.1016/j.annonc.2022.07.1940
Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S. A., . . . Dowsett, M. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist, 22(9), 1028-1038. https://doi.org/10.1634/theoncologist.2017-0072
Lopez, M., Papaldo, P., Di Lauro, L., Vici, P., Carpano, S., & Conti, E. M. (1989). 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology, 46(1), 1-5. https://doi.org/10.1159/000226671
Loprinzi, C. L. (1994). It is now the age to define the appropriate follow-up of primary breast cancer patients. Journal of clinical oncology, 12(5), 881-883. https://doi.org/Doi 10.1200/Jco.1994.12.5.881
Loprinzi, C. L., Kugler, J. W., Barton, D. L., Dueck, A. C., Tschetter, L. K., Nelimark, R. A., . . . Jaslowski, A. J. (2007). Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. Journal of clinical oncology, 25(3), 308-312. https://doi.org/10.1200/Jco.2006.07.5390
Lord, S., Ghersi, D., Gattellari, M., Wortley, S., Wilcken, N., & Simes, J. (2004). Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane database of systematic reviews, (4), CD003367. https://doi.org/10.1002/14651858.CD003367.pub2
Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). (2011). LOV-2011-06-24-30. Sist endret i LOV-2021-06-18-118 fra 01.09.2021, LOV-2021-06-18-127 fra 01.07.2021.
Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). (1999). LOV-1999-07-02-63.
Lu, W. L., Jansen, L., Post, W. J., Bonnema, J., Van de Velde, J. C., & De Bock, G. H. (2009). Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast cancer research and treatment, 114(3), 403-412. https://doi.org/10.1007/s10549-008-0023-4
Luck, H. J., & Roche, H. (2002). Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Critical Reviews in Oncology/Hematology, 44(Suppl), S15-S30. https://doi.org/10.1016/s1040-8428(02)00105-1
Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016). Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg, 212(4), 660-669. https://doi.org/10.1016/j.amjsurg.2016.06.010
Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B., III, Bodurka, D. C., Burstein, H. J., . . . Winer, E. P. (2005). American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of clinical oncology, 23(30), 7703-7720. https://doi.org/10.1200/JCO.2005.08.001
Lænkholm, A. V., Jensen, M. B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., . . . Ejlertsen, B. (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. Journal of clinical oncology, 36(8), 735-740. https://doi.org/10.1200/jco.2017.74.6586
Lønning, P. E., & Eikesdal, H. P. (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-related cancer, 20(4), R183-201. https://doi.org/10.1530/erc-13-0099
Lønning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jørgensen, L. M., . . . Howell, A. (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast cancer research and treatment, 67(2), 111-116. https://doi.org/10.1023/a:1010619225209
MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., . . . Lagios, M. (2005). Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. American journal of surgery, 190(4), 521-525. https://doi.org/10.1016/j.amjsurg.2005.06.005
Madorsky-Feldman, D., Sklair-Levy, M., Perri, T., Laitman, Y., Paluch-Shimon, S., Schmutzler, R., . . . Friedman, E. (2016). An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment, 157(2), 319-327. https://doi.org/10.1007/s10549-016-3805-0
Madsen, S. (2009). Planteøstrogener og overgangsplager hos kvinner. Tidsskrift for den norske legeforening, 129(21), 2238-2239.
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., . . . Seaman, J. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of clinical oncology, 19(2), 558-567. https://doi.org/Doi 10.1200/Jco.2001.19.2.558
Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Rastogi, P., . . . Wolmark, N. (2019). Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 20(1), 88-99. https://doi.org/10.1016/s1470-2045(18)30621-1
Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Rastogi, P., . . . Wolmark, N. (2020). Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research, 80(4 Suppl), GS4-01. https://doi.org/10.1158/1538-7445.SABCS19-GS4-01
Mann, R. M., Balleyguier, C., Baltzer, P. A., Bick, U., Colin, C., Cornford, E., . . . Sardanelli, F. (2015). Breast MRI: EUSOBI recommendations for women's information. European radiology, 25(12), 3669-3678. https://doi.org/10.1007/s00330-015-3807-z
Mann, R. M., Kuhl, C. K., Kinkel, K., & Boetes, C. (2008). Breast MRI: guidelines from the European Society of Breast Imaging. European radiology, 18(7), 1307-1318.
Mann, R. M., Loo, C. E., Wobbes, T., Bult, P., Barentsz, J. O., Gilhuijs, K. G., & Boetes, C. (2010). The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast cancer research and treatment, 119(2), 415-422. https://doi.org/10.1007/s10549-009-0616-6
Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O., . . . Darby, S. C. (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ, 369, m1570. https://doi.org/10.1136/bmj.m1570
Mansell, J., Weiler-Mithoff, E., Stallard, S., Doughty, J. C., Mallon, E., & Romics, L. (2017). Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast, 32, 179-185. https://doi.org/10.1016/j.breast.2017.02.006
Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., . . . Wactawski-Wende, J. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 318(10), 927-938. https://doi.org/10.1001/jama.2017.11217
Marinovich, M. L., Houssami, N., Macaskill, P., Sardanelli, F., Irwig, L., Mamounas, E. P., . . . Ciatto, S. (2013a). Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the National Cancer Institute, 105(5), 321-333. https://doi.org/10.1093/jnci/djs528
Marinovich, M. L., Macaskill, P., Irwig, L., Sardanelli, F., von Minckwitz, G., Mamounas, E., . . . Houssami, N. (2013b). Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. British Journal of Cancer, 109(6), 1528-1536. https://doi.org/10.1038/bjc.2013.473
Marinovich, M. L., Sardanelli, F., Ciatto, S., Mamounas, E., Brennan, M., Macaskill, P., . . . Houssami, N. (2012). Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast, 21(5), 669-677. https://doi.org/10.1016/j.breast.2012.07.006
Martaindale, S., Omofoye, T. S., Teichgraeber, D. C., Hess, K. R., & Whitman, G. J. (2020). Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Academic Radiology, 27(3), 389-394. https://doi.org/10.1016/j.acra.2019.05.012
Martelli, G., Boracchi, P., Ardoino, I., Lozza, L., Bohm, S., Vetrella, G., & Agresti, R. (2012). Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg, 256(6), 920-924. https://doi.org/10.1097/SLA.0b013e31827660a8
Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., . . . Chan, A. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(12), 1688-1700. https://doi.org/10.1016/s1470-2045(17)30717-9
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., . . . Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. The New England journal of medicine, 352(22), 2302-2313. https://doi.org/10.1056/NEJMoa043681
Martín, M., Ruiz Simón, A., Ruiz Borrego, M., Ribelles, N., Rodríguez-Lescure, Á., Muñoz-Mateu, M., . . . Lluch, A. (2015). Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Journal of clinical oncology, 33(32), 3788-3795. https://doi.org/10.1200/jco.2015.61.9510
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., . . . Extra, J. M. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of clinical oncology, 23(19), 4265-4274. https://doi.org/10.1200/Jco.2005.04.173
Masannat, Y. A., Bains, S. K., Pinder, S. E., & Purushotham, A. D. (2013). Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast, 22(2), 194-196. https://doi.org/10.1016/j.breast.2013.01.003
Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., . . . Toi, M. (2017). Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England journal of medicine, 376(22), 2147-2159. https://doi.org/10.1056/NEJMoa1612645
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., . . . de Bono, J. S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 162-174. https://doi.org/10.1016/s1470-2045(19)30684-9
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., . . . Embrace. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812-822. https://doi.org/10.1093/jnci/djt095
Mayer, I. A., Zhao, F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., . . . Miller, K. D. (2021). Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 39(23), 2539-2551. https://doi.org/10.1200/jco.21.00976
McCormack, P. M., Bains, M. S., Burt, M. E., Martini, N., Chaglassian, T., & Hidalgo, D. A. (1989). Local recurrent mammary carcinoma failing multimodality therapy. A solution. Archives of surgery, 124(2), 158-161. https://doi.org/10.1001/archsurg.1989.01410020028003
McCulley, S. J., Schaverien, M. V., Tan, V. K., & Macmillan, R. D. (2015). Lateral thoracic artery perforator (LTAP) flap in partial breast reconstruction. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 68(5), 686-691. https://doi.org/10.1016/j.bjps.2015.01.008
McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., . . . Darby, S. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, 383(9935), 2127-2135. https://doi.org/10.1016/s0140-6736(14)60488-8
McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., . . . Buchholz, T. A. (2007). Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. International journal of radiation oncology, biology, physics, 68(4), 1004-1009. https://doi.org/10.1016/j.ijrobp.2007.01.023
McNeely, M. L., Campbell, K., Ospina, M., Rowe, B. H., Dabbs, K., Klassen, T. P., . . . Courneya, K. (2010). Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane database of systematic reviews, (6), CD005211. https://doi.org/10.1002/14651858.CD005211.pub2
McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., & Hanson, J. (2004). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast cancer research and treatment, 86(2), 95-106. https://doi.org/10.1023/B:BREA.0000032978.67677.9f
Meattini, I., Becherini, C., Boersma, L., Kaidar-Person, O., Marta, G. N., Montero, A., . . . Coles, C. E. (2022). European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. The Lancet. Oncology, 23(1), e21-e31. https://doi.org/10.1016/s1470-2045(21)00539-8
Meattini, I., Marrazzo, L., Saieva, C., Desideri, I., Scotti, V., Simontacchi, G., . . . Livi, L. (2020). Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. Journal of clinical oncology, 38(35), 4175-4183. https://doi.org/10.1200/jco.20.00650
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., . . . Hortobagyi, G. N. (2019). Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. The New England journal of medicine, 380(13), 1226-1234. https://doi.org/10.1056/NEJMoa1811714
Meijers-Heijboer, H., van, G. B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., . . . Klijn, J. G. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine, 345(3), 159-164. https://doi.org/10.1056/NEJM200107193450301
Mendenhall, N. P., Devine, J. W., Mendenhall, W. M., Bland, K. I., Million, R. R., & Copeland, E. M., III. (1988). Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiotherapy and Oncology, 12(3), 177-185.
Menes, T. S., Tartter, P. I., Bleiweiss, I., Godbold, J. H., Estabrook, A., & Smith, S. R. (2005). The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Annals of surgical oncology, 12(11), 881-885. https://doi.org/10.1245/ASO.2005.03.021
Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., . . . Narod, S. A. (2014). Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ, 348, g226. https://doi.org/10.1136/bmj.g226
Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I., . . . Narod, S. A. (2015). Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA oncology, 1(3), 306-313. https://doi.org/10.1001/jamaoncol.2015.0658
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., . . . Narod, S. A. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of clinical oncology, 22(12), 2328-2335. https://doi.org/10.1200/JCO.2004.04.033
Michell, M. J., & Batohi, B. (2018). Role of tomosynthesis in breast imaging going forward. Clinical radiology, 73(4), 358-371. https://doi.org/10.1016/j.crad.2018.01.001
Mieog, J. S., van der Hage, J. A., & van de Velde, C. J. (2007). Neoadjuvant chemotherapy for operable breast cancer. The British journal of surgery, 94(10), 1189-1200. https://doi.org/10.1002/bjs.5894
Miles, D. W., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C. H., . . . O'Shaughnessy, J. (2020). Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology, 31(Suppl 4), S1147-S1148. https://doi.org/10.1016/j.annonc.2020.08.2243
Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., Gonzalez-Angulo, A. M., . . . Hunt, K. K. (2011). Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. Journal of clinical oncology, 29(15), 1956-1962. https://doi.org/10.1200/jco.2010.31.8469
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., . . . Harbeck, N. (2020). Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet, 396(10257), 1090-1100. https://doi.org/10.1016/s0140-6736(20)31953-x
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., . . . Cameron, D. A. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England journal of medicine, 387(1), 9-20. https://doi.org/10.1056/NEJMoa2203690
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., . . . Krop, I. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. The New England journal of medicine, 382(7), 610-621. https://doi.org/10.1056/NEJMoa1914510
Moinfar, F., Man, Y. G., Bratthauer, G. L., Ratschek, M., & Tavassoli, F. A. (2000). Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer, 88(9), 2072-2081. https://doi.org/Doi 10.1002/(Sici)1097-0142(20000501)88:9<2072::Aid-Cncr13>3.3.Co;2-8
Mokbel, K., & Cutuli, B. (2006). Heterogeneity of ductal carcinoma in situ and its effects on management. The Lancet. Oncology, 7(9), 756-765. https://doi.org/10.1016/S1470-2045(06)70861-0
Molina-Montes, E., Perez-Nevot, B., Pollan, M., Sanchez-Cantalejo, E., Espin, J., & Sanchez, M. J. (2014). Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast, 23(6), 721-742. https://doi.org/10.1016/j.breast.2014.10.005
Moller, P., Evans, D. G., Reis, M. M., Gregory, H., Anderson, E., Maehle, L., . . . Steel, C. M. (2007). Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. International Journal of Cancer, 121(5), 1017-1020. https://doi.org/10.1002/ijc.22789
Montgomery, D. A., Krupa, K., & Cooke, T. G. (2007). Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. British Journal of Cancer, 97(12), 1632-1641. https://doi.org/10.1038/sj.bjc.6604065
Moore, H. C. F., Unger, J. M., Phillips, K.-A., Boyle, F., Hitre, E., Porter, D., . . . Albain, K. S. (2015). Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. The New England journal of medicine, 372(10), 923-932. https://doi.org/10.1056/NEJMoa1413204
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., . . . Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20(5), 636-648. https://doi.org/10.1016/S1470-2045(19)30029-4
Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., . . . Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. Journal of clinical oncology, 31(33), 4188-4198. https://doi.org/10.1200/jco.2013.48.9021
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., . . . Morrow, M. (2014). Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Annals of surgical oncology, 21(3), 704-716. https://doi.org/10.1245/s10434-014-3481-4
Morante, Z., Ruiz, R., De la Cruz - Ku, G., Namuche, F., Mantilla, R., Lujan, M. G., . . . Gomez, H. (2019). Abstract GS2-05: Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer. Cancer Research, 79(4 Suppl), GS2-05. https://doi.org/10.1158/1538-7445.SABCS18-GS2-05
Moravek, M. B., Confino, R., Smith, K. N., Kazer, R. R., Klock, S. C., Lawson, A. K., . . . Pavone, M. E. (2018). Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertility and Sterility, 109(2), 349-355. https://doi.org/10.1016/j.fertnstert.2017.10.029
Morrow, M., Schnitt, S. J., & Norton, L. (2015). Current management of lesions associated with an increased risk of breast cancer. Nature reviews. Clinical oncology, 12(4), 227-238. https://doi.org/10.1038/nrclinonc.2015.8
Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., . . . Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of clinical oncology, 34(33), 4040-4046. https://doi.org/10.1200/jco.2016.68.3573
Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016). Follow-up strategies for women treated for early breast cancer. Cochrane database of systematic reviews, 2016(5), CD001768. https://doi.org/10.1002/14651858.CD001768.pub3
Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thurlimann, B., Paridaens, R., Smith, I., . . . Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England journal of medicine, 361(8), 766-776. https://doi.org/10.1056/NEJMoa0810818
Moy, B., Rumble, R. B., & Carey, L. A. (2022). Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. Journal of clinical oncology, 40(26), 3088-3090. https://doi.org/10.1200/jco.22.01533
Mulder, R. L., Hudson, M. M., Bhatia, S., Landier, W., Levitt, G., Constine, L. S., . . . Oeffinger, K. C. (2020). Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. Journal of clinical oncology, 38(35), 4194-4207. https://doi.org/10.1200/jco.20.00562
Murphy, C., Anderson, P. R., Li, T., Bleicher, R. J., Sigurdson, E. R., Goldstein, L. J., . . . Freedman, G. M. (2011). Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. International journal of radiation oncology, biology, physics, 81(1), 69-76. https://doi.org/10.1016/j.ijrobp.2010.04.067
Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., . . . Yarnold, J. R. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, 395(10237), 1613-1626. https://doi.org/10.1016/s0140-6736(20)30932-6
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., . . . Winer, E. P. (2020). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England journal of medicine, 382(7), 597-609. https://doi.org/10.1056/NEJMoa1914609
Muscolino, G., Valente, M., Lequaglie, C., & Ravasi, G. (1992). Correlation between first disease-free interval from mastectomy to second disease-free interval from chest wall resection. European journal of surgical oncology, 18(1), 49-52.
Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortes, J., . . . Andre, F. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research, 19(1), 18. https://doi.org/10.1186/s13058-017-0807-8
Muss, H. B., Biganzoli, L., Sargent, D. J., & Aapro, M. (2007). Adjuvant therapy in the elderly: making the right decision. Journal of clinical oncology, 25(14), 1870-1875. https://doi.org/10.1200/JCO.2006.10.3457
Muss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., . . . Goss, P. E. (2008). Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. Journal of clinical oncology, 26(12), 1956-1964. https://doi.org/10.1200/JCO.2007.12.6334
Myckatyn, T. M., Wagner, I. J., Mehrara, B. J., Crosby, M. A., Park, J. E., Qaqish, B. F., . . . Lee, C. N. (2017). Cancer Risk after Fat Transfer: A Multicenter Case-Cohort Study. Plastic and reconstructive surgery, 139(1), 11-18. https://doi.org/10.1097/PRS.0000000000002838
Möbus, V., Diel, I. J., Elling, D., Harbeck, N., Jackisch, C., Thomssen, C., . . . al., e. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. (Abstract [S2-4] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-4
Møller, P., Hagen, A. I., Apold, J., Maehle, L., Clark, N., Fiane, B., . . . Vabo, A. (2007). Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. European journal of cancer, 43(11), 1713-1717. https://doi.org/10.1016/j.ejca.2007.04.023
Møller, P., Stormorken, A., Holmen, M. M., Hagen, A. I., Vabø, A., & Mæhle, L. (2014). The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation. Breast cancer research and treatment, 144(3), 607-614. https://doi.org/10.1007/s10549-014-2902-1
Møller, P., Stormorken, A., Jonsrud, C., Holmen, M. M., Hagen, A. I., Clark, N., . . . Mæhle, L. (2013). Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast cancer research and treatment, 139(1), 155-161. https://doi.org/10.1007/s10549-013-2540-z
Nabholtz, J. M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschenes, L., Douma, J., . . . Aapro, M. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of clinical oncology, 17(5), 1413-1424. https://doi.org/10.1200/JCO.1999.17.5.1413
Nagaraja, V., Edirimanne, S., & Eslick, G. D. (2016). Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis. The breast journal, 22(2), 158-165. https://doi.org/10.1111/tbj.12549
Natori, A., Ethier, J. L., Amir, E., & Cescon, D. W. (2017). Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European journal of cancer, 77, 40-47. https://doi.org/10.1016/j.ejca.2017.02.024
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., . . . Wagle, N. (2018). Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature genetics, 51(2), 207-216. https://doi.org/10.1038/s41588-018-0287-5
NCCN. (2016). NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Genetic/Familial High-Risk assessment: breast and ovarian. Version 1.2016. Fort Washington, PA: National Coprehensive Cancer Network.
NCCN. (2018). NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer. Version 1.2018. Fort Washington, PA: National Comprehensive Cancer Network.
NCCN. (2022). NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer. Version 2.2022. Fort Washington, PA: National Comprehensive Cancer Network.
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., . . . Humphrey, L. (2006). Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 295(17), 2057-2071. https://doi.org/10.1001/jama.295.17.2057
Nelson, J. A., Allen, R. J., Jr., Polanco, T., Shamsunder, M., Patel, A. R., McCarthy, C. M., . . . Pusic, A. L. (2019). Long-term Patient-reported Outcomes Following Postmastectomy Breast Reconstruction: An 8-year Examination of 3268 Patients. Annals of surgery, 270(3), 473-483. https://doi.org/10.1097/sla.0000000000003467
NICE. (20. november 2019). Early detection of breast cancer by surveillance. I: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline [CG164]. [nettdokument]. London: National Institute for Health and Care Excellence. Hentet 11. mai 2020, fra https://www.nice.org.uk/guidance/cg164/ifp/chapter/Early-detection-of-breast-cancer-by-surveillance
Nichol, A., Narinesingh, D., Raman, S., Germain, F., Chan, E. K., Tran, E., . . . Truong, P. (2021). The Effect of Bolus on Local Control for Patients Treated With Mastectomy and Radiation Therapy. International journal of radiation oncology, biology, physics, 110(5), 1360-1369. https://doi.org/10.1016/j.ijrobp.2021.01.019
Nichols, H. B., Berrington de González, A., Lacey, J. V., Jr., Rosenberg, P. S., & Anderson, W. F. (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. Journal of clinical oncology, 29(12), 1564-1569. https://doi.org/10.1200/jco.2010.32.7395
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., . . . Ellis, M. J. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer research, 16(21), 5222-5232. https://doi.org/10.1158/1078-0432.ccr-10-1282
Nieweg, O. E., & Bartelink, H. (2004). Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. European journal of cancer, 40(2), 179-181. https://doi.org/10.1016/j.ejca.2003.09.026
Nilsson, C., & Valachis, A. (2015). The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiotherapy and Oncology, 114(1), 50-55. https://doi.org/10.1016/j.radonc.2015.01.001
Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, A., Henriksson, K., . . . Loman, N. (2014). High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast cancer research and treatment, 147(3), 571-578. https://doi.org/10.1007/s10549-014-3115-3
Nitz, U., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., . . . Harbeck, N. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of clinical oncology, 37(10), 799-808. https://doi.org/10.1200/jco.18.00028
Njor, S., Nystrom, L., Moss, S., Paci, E., Broeders, M., Segnan, N., & Lynge, E. (2012). Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. Journal of medical screening, 19 Suppl 1, 33-41. https://doi.org/10.1258/jms.2012.012080
Norsk bryst cancer gruppe. (2011). NBCGs hehandlingsanbefalinger "Blåboka". [nettdokument]. Hentet 13. feb. 2013
Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., & Rutqvist, L. E. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359(9310), 909-919. https://doi.org/10.1016/S0140-6736(02)08020-0
O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., . . . Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology, 15(3), 440-449. https://doi.org/10.1093/annonc/mdh097
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., . . . Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. The New England journal of medicine, 364(3), 205-214. https://doi.org/10.1056/NEJMoa1011418
O'Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., . . . Hortobagyi, G. N. (2018). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast cancer research and treatment, 168(1), 127-134. https://doi.org/10.1007/s10549-017-4518-8
Offersen, B., Nielsen, H. M., Jacobsen, E. H., Nielsen, M. H., Krause, M., Stenbygaard, L., . . . Overgaard, J. (2018). OC-0596: Hypo- vs normofractionated radiation of early breast cancer in the randomized DBCG HYPO trial. Radiotherapy and Oncology, 127(Suppl 1), S312. https://doi.org/10.1016/S0167-8140(18)30906-X
Offersen, B. V., Alsner, J., Nielsen, H. M., Jakobsen, E. H., Nielsen, M. H., Krause, M., . . . Overgaard, J. (2020). Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of clinical oncology, 38(31), 3615-3625. https://doi.org/10.1200/jco.20.01363
Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Biete Sola, A., . . . Poortmans, P. (2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy and Oncology, 114(1), 3-10. https://doi.org/10.1016/j.radonc.2014.11.030
Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., . . . Poortmans, P. (2016). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiotherapy and Oncology, 118(1), 205-208. https://doi.org/10.1016/j.radonc.2015.12.027
Offersen, B. V., Overgaard, M., Kroman, N., & Overgaard, J. (2009). Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiotherapy and Oncology, 90(1), 1-13. https://doi.org/10.1016/j.radonc.2008.08.005
Olinger, T. A., Berlin, N. L., Qi, J., Hamill, J. B., Kim, H. M., Pusic, A. L., . . . Momoh, A. O. (2020). Outcomes of Immediate Implant-Based Mastectomy Reconstruction in Women with Previous Breast Radiotherapy. Plastic and reconstructive surgery, 145(6), 1029e-1036e. https://doi.org/10.1097/PRS.0000000000006811
Olivotto, I. A., Lesperance, M. L., Truong, P. T., Nichol, A., Berrang, T., Tyldesley, S., . . . Kennecke, H. (2009). Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. Journal of clinical oncology, 27(1), 16-23.
Orecchia, R., Veronesi, U., Maisonneuve, P., Galimberti, V. E., Lazzari, R., Veronesi, P., . . . Intra, M. (2021). Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. The Lancet. Oncology, 22(5), 597-608. https://doi.org/10.1016/s1470-2045(21)00080-2
Osswald, R., Boss, A., Lindenblatt, N., Vorburger, D., & Dedes, K. (2020). Does lipofilling after oncologic breast surgery increase the amount of suspicious imaging and required biopsies?-A systematic meta-analysis. The breast journal, 26(5), 847-859. https://doi.org/10.1111/tbj.13514
Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Christensen, I. J., & Andersen, J. A. (2000). Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast cancer research and treatment, 62(3), 197-210. https://doi.org/10.1023/a:1006453915590
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., . . . Zedeler, K. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. The New England journal of medicine, 337(14), 949-955. https://doi.org/10.1056/NEJM199710023371401
Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., . . . Mouridsen, H. T. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, 353(9165), 1641-1648. https://doi.org/10.1016/S0140-6736(98)09201-0
Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., . . . Regan, M. M. (2020). Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Journal of clinical oncology, 38(12), 1293-1303. https://doi.org/10.1200/jco.18.01967
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Lang, I., . . . Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 371(2), 107-118. https://doi.org/10.1056/NEJMoa1404037
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., . . . Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of clinical oncology, 24(23), 3726-3734. https://doi.org/10.1200/jco.2005.04.7985
Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del, T. M., Distante, V., & Pacini, P. (1999). Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA, 281(17), 1586. https://doi.org/10.1001/jama.281.17.1586
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., . . . Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. The New England journal of medicine, 377(19), 1836-1846. https://doi.org/10.1056/NEJMoa1701830
Panayi, A. C., Foroutanjazi, S., Parikh, N., Haug, V., Kauke-Navarro, M., Diehm, Y. F., & Pomahac, B. (2022). The modified 5-item frailty index is a predictor of perioperative risk in breast reconstruction: An analysis of 40,415 cases. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 75(9), 2941-2954. https://doi.org/10.1016/j.bjps.2022.04.035
Pandya, K. J., Raubertas, R. F., Flynn, P. J., Hynes, H. E., Rosenbluth, R. J., Kirshner, J. J., . . . Morrow, G. R. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of internal medicine, 132(10), 788-793. https://doi.org/10.7326/0003-4819-132-10-200005160-00004
Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A. M., Di, C. B., . . . Cognetti, F. (2006). A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Annals of oncology, 17(4), 630-636. https://doi.org/10.1093/annonc/mdj110
Parazzini, F., Colli, E., Scatigna, M., & Tozzi, L. (1993). Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology, 50(6), 483-489. https://doi.org/10.1159/000227233
Park, Y. H., Kim, T. Y., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., . . . Im, S. A. (2019). Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 20(12), 1750-1759. https://doi.org/10.1016/s1470-2045(19)30565-0
Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., . . . Smith, I. E. (2014). Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology, 32(29), 3307-3329. https://doi.org/10.1200/jco.2014.56.7479
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of clinical oncology, 21(4), 602-606. https://doi.org/10.1200/jco.2003.07.071
Paterson, A. H. G., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., . . . al., e. (2011). NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (Abstract [S2-3] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-3
Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 24 Suppl 6, vi160-170. https://doi.org/10.1093/annonc/mdt199
Peled, A. W., Irwin, C. S., Hwang, E. S., Ewing, C. A., Alvarado, M., & Esserman, L. J. (2014). Total skin-sparing mastectomy in BRCA mutation carriers. Annals of surgical oncology, 21(1), 37-41. https://doi.org/10.1245/s10434-013-3230-0
Penault-Llorca, F., Andre, F., Sagan, C., Lacroix-Triki, M., Denoux, Y., Verriele, V., . . . Roche, H. (2009). Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Journal of clinical oncology, 27(17), 2809-2815. https://doi.org/10.1200/JCO.2008.18.2808
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E., Jr., . . . Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of clinical oncology, 32(33), 3744-3752. https://doi.org/10.1200/jco.2014.55.5730
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., . . . Jenkins, R. B. (2011). Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of clinical oncology, 29(34), 4491-4497. https://doi.org/10.1200/JCO.2011.36.7045
Peters, N. H., van Esser, S., van den Bosch, M. A., Storm, R. K., Plaisier, P. W., van Dalen, T., . . . Peeters, P. H. (2011). Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. European journal of cancer, 47(6), 879-886. https://doi.org/10.1016/j.ejca.2010.11.035
Petit, J. Y., Botteri, E., Lohsiriwat, V., Rietjens, M., De Lorenzi, F., Garusi, C., . . . Rotmensz, N. (2012). Locoregional recurrence risk after lipofilling in breast cancer patients. Annals of oncology, 23(3), 582-588. https://doi.org/10.1093/annonc/mdr158
Petit, J. Y., Maisonneuve, P., Rotmensz, N., Bertolini, F., & Rietjens, M. (2017). Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plastic and reconstructive surgery, 139(6), 1292-1296. https://doi.org/10.1097/PRS.0000000000003339
Petit, J. Y., Rietjens, M., Botteri, E., Rotmensz, N., Bertolini, F., Curigliano, G., . . . Lohsiriwat, V. (2013). Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. Annals of oncology, 24(6), 1479-1484. https://doi.org/10.1093/annonc/mds660
Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., . . . Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432-444. https://doi.org/10.1016/S0140-6736(11)61625-5
Petruolo, O. A., Pilewskie, M., Patil, S., Barrio, A. V., Stempel, M., Wen, H. Y., & Morrow, M. (2017). Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of surgical oncology, 24(9), 2556-2562. https://doi.org/10.1245/s10434-017-5898-z
Phi, X. A., Houssami, N., Obdeijn, I. M., Warner, E., Sardanelli, F., Leach, M. O., . . . de Bock, G. H. (2015). Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age >/= 50 years: evidence from an individual patient data meta-analysis. Journal of clinical oncology, 33(4), 349-356. https://doi.org/10.1200/JCO.2014.56.6232
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., . . . Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England journal of medicine, 353(16), 1659-1672. https://doi.org/10.1056/NEJMoa052306
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., . . . Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Annals of oncology, 25(12), 2357-2362. https://doi.org/10.1093/annonc/mdu456
Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., . . . Thomssen, C. (2020). Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. Cancer Research, 80(4 Suppl), GS1-04. https://doi.org/10.1158/1538-7445.SABCS19-GS1-04
Piccart, M., van 't Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J. Y., . . . Rutgers, E. J. T. (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. The Lancet. Oncology, 22(4), 476-488. https://doi.org/10.1016/s1470-2045(21)00007-3
Piccart, M. J., de Valeriola, D., Dal Lago, L., de Azambuja, E., Demonty, G., Lebrun, F., . . . Cufer, T. (2005). Adjuvant chemotherapy in 2005: standards and beyond. Breast, 14(6), 439-445. https://doi.org/10.1016/j.breast.2005.08.004
Piper, M., Peled, A. W., Sbitany, H., Foster, R. D., Esserman, L. J., & Price, E. R. (2016). Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Annals of surgical oncology, 23(1), 65-71. https://doi.org/10.1245/s10434-015-4611-3
Pivot, X., Romieu, G., Debled, M., Pierga, J. Y., Kerbrat, P., Bachelot, T., . . . Kramar, A. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet. Oncology, 14(8), 741-748. https://doi.org/10.1016/s1470-2045(13)70225-0
Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., . . . Lambertini, M. (2018). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of oncology, 29(7), 1497-1508. https://doi.org/10.1093/annonc/mdy127
Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., . . . Van den Bogaert, W. (2015). Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. The New England journal of medicine, 373(4), 317-327. https://doi.org/10.1056/NEJMoa1415369
Potter, S., Conroy, E. J., Cutress, R. I., Williamson, P. R., Whisker, L., Thrush, S., . . . Holcombe, C. (2019). Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. The Lancet. Oncology, 20(2), 254-266. https://doi.org/10.1016/s1470-2045(18)30781-2
Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., . . . Gavilá, J. (2020). Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 33-43. https://doi.org/10.1016/s1470-2045(19)30786-7
Pronzato, P., Campora, E., Amoroso, D., Bertelli, G., Botto, F., Conte, P. F., . . . Rosso, R. (1989). Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. American journal of clinical oncology, 12(6), 481-485. https://doi.org/10.1097/00000421-198912000-00004
Quiet, C. A., Ferguson, D. J., Weichselbaum, R. R., & Hellman, S. (1995). Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. Journal of clinical oncology, 13(5), 1144-1151. https://doi.org/10.1200/JCO.1995.13.5.1144
Radovanovic, Z., Ranisavljevic, M., Radovanovic, D., Vicko, F., Ivkovic-Kapicl, T., & Solajic, N. (2018). Nipple-Sparing Mastectomy with Primary Implant Reconstruction: Surgical and Oncological Outcome of 435 Breast Cancer Patients. Breast Care (Basel), 13(5), 373-378. https://doi.org/10.1159/000489317
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., . . . Olivotto, I. A. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. The New England journal of medicine, 337(14), 956-962. https://doi.org/10.1056/NEJM199710023371402
Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., . . . Manji, M. (2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute, 97(2), 116-126. https://doi.org/10.1093/jnci/djh297
Rageth, C. J., O'Flynn, E. A. M., Pinker, K., Kubik-Huch, R. A., Mundinger, A., Decker, T., . . . Varga, Z. (2019). Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast cancer research and treatment, 174(2), 279-296. https://doi.org/10.1007/s10549-018-05071-1
Rakha, E. A., Pinder, S. E., Bartlett, J. M., Ibrahim, M., Starczynski, J., Carder, P. J., . . . Ellis, I. O. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. Journal of clinical pathology, 68(2), 93-99. https://doi.org/10.1136/jclinpath-2014-202571
Rakovitch, E., Nofech-Mozes, S., Narod, S. A., Hanna, W., Thiruchelvam, D., Saskin, R., . . . Paszat, L. (2013). Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast cancer research and treatment, 138(2), 581-590. https://doi.org/10.1007/s10549-013-2455-8
Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., . . . Lin, N. U. (2018). Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 36(27), 2804-2807. https://doi.org/10.1200/jco.2018.79.2713
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., . . . Wolmark, N. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of clinical oncology, 26(5), 778-785. https://doi.org/10.1200/JCO.2007.15.0235
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., . . . Baselga, J. (2018). The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 34(3), 427-438 e426. https://doi.org/10.1016/j.ccell.2018.08.008
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van, t., V, Garber, J. E., . . . Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of clinical oncology, 22(6), 1055-1062. https://doi.org/10.1200/JCO.2004.04.188
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80-87. https://doi.org/10.1093/jnci/djn442
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., . . . Edge, S. B. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical radiation oncology, 6(6), e219-e234. https://doi.org/10.1016/j.prro.2016.08.009
Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., . . . Pfister, D. G. (2001). Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. Journal of clinical oncology, 19(5), 1539-1569. https://doi.org/10.1200/JCO.2001.19.5.1539
Reed, W., Hannisdal, E., Boehler, P. J., Gundersen, S., Host, H., & Marthin, J. (2000). The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88(4), 804-813. https://doi.org/Doi 10.1002/(Sici)1097-0142(20000215)88:4<804::Aid-Cncr11>3.0.Co;2-Y
Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., . . . Thurlimann, B. (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. The Lancet. Oncology, 12(12), 1101-1108. https://doi.org/10.1016/S1470-2045(11)70270-4
Regan, M. M., Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Kammler, R., . . . Viale, G. (2015). Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast cancer research and treatment, 154(2), 275-286. https://doi.org/10.1007/s10549-015-3612-z
Regionalt cancercentrum. (2014). Bröstcancer: Nationellt vårdprogram. Stockholm: Regionalt cancercentrum. Hentet fra http://www.swebcg.se/wp-content/uploads/2016/09/NVP-Br%C3%B6stcancer-2014.pdf
Reinertsen, K. V., Cvancarova, M., Wist, E., Bjøro, T., Dahl, A. A., Danielsen, T., & Fossa, S. D. (2009). Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. International journal of radiation oncology, biology, physics, 75(3), 764-770. https://doi.org/10.1016/j.ijrobp.2008.11.037
Research Council of Norway. (2015). Research based evaluation of the Norwegian Breast Cancer Screening Program: final report. Oslo: Research Council of Norway. Hentet fra https://www.regjeringen.no/contentassets/444d08daf15e48aca5321f2cefaac511/mammografirapport-til-web.pdf
Rigakos, G., & Razis, E. (2012). BRCAness: finding the Achilles heel in ovarian cancer. Oncologist, 17(7), 956-962. https://doi.org/10.1634/theoncologist.2012-0028
Rimawi, M., Ferrero, J. M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., . . . Arpino, G. (2018). First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of clinical oncology, 36(28), 2826-2835. https://doi.org/10.1200/jco.2017.76.7863
Robert, N. J., Vogel, C. L., Henderson, I. C., Sparano, J. A., Moore, M. R., Silverman, P., . . . Gabizon, A. A. (2004). The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in oncology, 31(6 Suppl 13), 106-146. https://doi.org/10.1053/j.seminoncol.2004.09.018
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., . . . Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/s0140-6736(16)32389-3
Robertson, S. A., Rusby, J. E., & Cutress, R. I. (2014). Determinants of optimal mastectomy skin flap thickness. The British journal of surgery, 101(8), 899-911. https://doi.org/10.1002/bjs.9470
Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., . . . Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England journal of medicine, 377(6), 523-533. https://doi.org/10.1056/NEJMoa1706450
Robson, M. E., Tung, N., Conte, P., Im, S. A., Senkus, E., Xu, B., . . . Domchek, S. M. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology, 30(4), 558-566. https://doi.org/10.1093/annonc/mdz012
Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., . . . Liberati, A. (2005). Follow-up strategies for women treated for early breast cancer. Cochrane database of systematic reviews, (1), CD001768. https://doi.org/10.1002/14651858.CD001768.pub2
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., . . . Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine, 353(16), 1673-1684. https://doi.org/10.1056/NEJMoa052122
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., . . . Ambros, Y. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal, 7(5), 377-387.
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., . . . Seaman, J. J. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735-1744. https://doi.org/10.1002/cncr.11701
Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989a). Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. Journal of clinical oncology, 7(9), 1239-1251. https://doi.org/10.1200/jco.1989.7.9.1239
Rosen, P. R., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989b). A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. Journal of clinical oncology, 7(3), 355-366. https://doi.org/10.1200/jco.1989.7.3.355
Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., . . . Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321
Rubino, C., Arriagada, R., Delaloge, S., & Lê, M. G. (2010). Relation of risk of contralateral breast cancer to the interval since the first primary tumour. British Journal of Cancer, 102(1), 213-219. https://doi.org/10.1038/sj.bjc.6605434
Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., Rey, P., . . . Coates, A. S. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Journal of clinical oncology, 24(3), 337-344. https://doi.org/10.1200/jco.2005.01.5784
Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., . . . Winer, E. P. (2015). Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of clinical oncology, 33(21), 2361-2369. https://doi.org/10.1200/jco.2014.59.5298
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., . . . Slamon, D. J. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast cancer research and treatment, 174(3), 719-729. https://doi.org/10.1007/s10549-018-05125-4
Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Borrego, M. R., Neven, P., . . . Chia, S. K. L. (2020). Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. Journal of Clinical Oncology, 38(15_suppl), 1006. https://doi.org/10.1200/JCO.2020.38.15_suppl.1006
Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M. B., Ejlertsen, B., de Azambuja, E., . . . Regan, M. M. (2019). Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of clinical oncology, 37(2), 105-114. https://doi.org/10.1200/jco.18.00440
Rusby, J. E., Paramanathan, N., Laws, S. A., & Rainsbury, R. M. (2008). Immediate latissimus dorsi miniflap volume replacement for partial mastectomy: use of intra-operative frozen sections to confirm negative margins. Am J Surg, 196(4), 512-518. https://doi.org/10.1016/j.amjsurg.2008.06.026
Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Journal of the National Cancer Institute, 100(15), 1058-1067. https://doi.org/10.1093/jnci/djn206
Sabate, J. M., Clotet, M., Torrubia, S., Gomez, A., Guerrero, R., de las Heras, P., & Lerma, E. (2007). Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics, 27 Suppl 1, S101-124. https://doi.org/10.1148/rg.27si075505
Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., . . . Gabizon, A. (2000). Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals of oncology, 11(8), 1029-1033. https://doi.org/10.1023/a:1008365716693
Safran, T., Al-Halabi, B., Viezel-Mathieu, A., Boileau, J. F., & Dionisopoulos, T. (2021). Skin-Reducing Mastectomy with Immediate Prepectoral Reconstruction: Surgical, Aesthetic, and Patient-Reported Outcomes with and without Dermal Matrices. Plastic and reconstructive surgery, 147(5), 1046-1057. https://doi.org/10.1097/PRS.0000000000007899
Sagen, A., Kåresen, R., & Risberg, M. A. (2009). Influence of physical activity on the development on arm lymphedema after breast cancer surgery. A prospective randomized controlled trial with two years follow-up. Acta Oncol, 48(4), 1102-1110.
Sakakibara, M., Nagashima, T., Sangai, T., Nakamura, R., Fujimoto, H., Arai, M., . . . Miyazaki, M. (2008). Breast-conserving surgery using projection and reproduction techniques of surgical-position breast MRI in patients with ductal carcinoma in situ of the breast. Journal of the American College of Surgeons, 207(1), 62-68. https://doi.org/10.1016/j.jamcollsurg.2007.12.034
Salibian, A. A., Bekisz, J. M., Kussie, H. C., Thanik, V. D., Levine, J. P., Choi, M., & Karp, N. S. (2021). Do We Need Support in Prepectoral Breast Reconstruction? Comparing Outcomes with and without ADM. Plastic and reconstructive surgery. Global open, 9(8), e3745. https://doi.org/10.1097/GOX.0000000000003745
Salibian, A. A., Frey, J. D., Bekisz, J. M., Karp, N. S., & Choi, M. (2019a). Ischemic Complications after Nipple-sparing Mastectomy: Predictors of Reconstructive Failure in Implant-based Reconstruction and Implications for Decision-making. Plastic and reconstructive surgery. Global open, 7(5), e2280. https://doi.org/10.1097/GOX.0000000000002280
Salibian, A. A., Frey, J. D., Karp, N. S., & Choi, M. (2019b). Does Staged Breast Reduction before Nipple-Sparing Mastectomy Decrease Complications? A Matched Cohort Study between Staged and Nonstaged Techniques. Plastic and reconstructive surgery, 144(5), 1023-1032. https://doi.org/10.1097/PRS.0000000000006121
Salvadori, B., Rovini, D., Squicciarini, P., Conti, R., Cusumano, F., & Grassi, M. (1992). Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. European journal of surgical oncology, 18(5), 438-441.
Samuel, J. A., Wilson, J. W., Bandos, H., Ellede, R. M., Robidoux, A., Fehrenbacher, L., . . . Brufsky, A. M. (2014). NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. på The 2014 San Antonio Breast Cancer Symposium, Abstrakt nummer S3-02. Hentet fra https://www.sabcs.org/Portals/SABCS/Documents/2014SABCSCall4Abstracts.pdf
Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., . . . Wilson, R. (2010). Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. European journal of cancer, 46(8), 1296-1316. https://doi.org/10.1016/j.ejca.2010.02.015
Sardanelli, F., Fallenberg, E. M., Clauser, P., Trimboli, R. M., Camps-Herrero, J., Helbich, T. H., & Forrai, G. (2017). Mammography: an update of the EUSOBI recommendations on information for women. Insights Imaging, 8(1), 11-18. https://doi.org/10.1007/s13244-016-0531-4
Saura, C., Oliveira, M., Feng, Y. H., Dai, M. S., Chen, S. W., Hurvitz, S. A., . . . Investigators, N. (2020). Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of clinical oncology, 38(27), 3138-3149. https://doi.org/10.1200/JCO.20.00147
Sawaki, M., Taira, N., Uemura, Y., Saito, T., Baba, S., Kobayashi, K., . . . Mukai, H. (2020). Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of clinical oncology, 38(32), 3743-3752. https://doi.org/10.1200/jco.20.00184
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., . . . Baselga, J. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute, 99(8), 628-638. https://doi.org/99/8/628 [pii]
10.1093/jnci/djk134
Schaverien, M. V., Stallard, S., Dodwell, D., & Doughty, J. C. (2013). Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. European journal of surgical oncology, 39(11), 1179-1185. https://doi.org/10.1016/j.ejso.2013.07.240
Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Del Mastro, L., . . . Generali, D. (2020). Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 112(11), 1089-1097. https://doi.org/10.1093/jnci/djaa071
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., . . . Turner, N. C. (2020a). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of clinical oncology, 38(5), 423-433. https://doi.org/10.1200/JCO.19.00368
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., . . . O'Shaughnessy, J. (2022). Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. The New England journal of medicine, 386(6), 556-567. https://doi.org/10.1056/NEJMoa2112651
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., . . . Emens, L. A. (2020b). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21(1), 44-59. https://doi.org/10.1016/s1470-2045(19)30689-8
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., . . . Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA oncology, 5(11), 1556-1563. https://doi.org/10.1001/jamaoncol.2019.2526
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, B. M., . . . Schwartz, A. L. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine and science in sports and exercise, 42(7), 1409-1426. https://doi.org/10.1249/MSS.0b013e3181e0c112
Schnitt, S., Collins, L. C., Lakhani, S. R., & Simpson, P. (2019). Flat epithelial atypi. I: WHO Classification of Tumours Editorial Board (red.), WHO classification of tumours of the Breast, Volume 2 (5 utg., s. 15-17). Lyon: IARC Press.
Schnitt, S. J., & Collins, L. C. (2005). Columnar Cell Lesions and Flat Epithelial Atypia of the Breast. Seminars in Breast Disease, 8(2), 100-111. https://doi.org/10.1053/j.sembd.2006.06.007
Schnitt, S. J., & Vincent-Salomon, A. (2003). Columnar cell lesions of the breast. Advances in anatomic pathology, 10(3), 113-124. https://doi.org/10.1097/00125480-200305000-00001
Schou Bredal, I., Smeby, N. A., Ottesen, S., Warncke, T., & Schlichting, E. (2014). Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. Journal of pain and symptom management, 48(5), 852-862. https://doi.org/10.1016/j.jpainsymman.2013.12.239
Schouten van der Velden, A. P., Peeters, P. H., Koot, V. C., & Hennipman, A. (2006). Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Annals of surgical oncology, 13(7), 990-998.
Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., . . . Brauch, H. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 302(13), 1429-1436. https://doi.org/DOI 10.1001/jama.2009.1420
Schuck, A., Konemann, S., Heinen, K., Rube, C. E., Hesselmann, S., Reinartz, G., . . . Willich, N. (2002). Microscopic residual disease is a risk factor in the primary treatment of breast cancer. Strahlentherapie und Onkologie, 178(6), 307-313. https://doi.org/10.1007/s00066-002-0950-7
Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., & Goodman, R. L. (1991). The results of radiation therapy for isolated local regional recurrence after mastectomy. International journal of radiation oncology, biology, physics, 21(2), 299-310. https://doi.org/10.1016/0360-3016(91)90775-y
Schwartz, G. F., Solin, L. J., Olivotto, I. A., Ernster, V. L., & Pressman, P. I. (2000). Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer, 88(4), 946-954.
Schwartz, J. D. (2019). Toward a More Definitive Goldilocks Mastectomy: Simultaneous Addition of the Lateral Intercostal Perforator Flap. Plastic and reconstructive surgery. Global open, 7(3), e2132. https://doi.org/10.1097/GOX.0000000000002132
Sechopoulos, I., Suryanarayanan, S., Vedantham, S., D'Orsi, C. J., & Karellas, A. (2008). Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology, 246(2), 434-443. https://doi.org/10.1148/radiol.2462070256
Seminog, O. O., & Goldacre, M. J. (2015). Age-specific risk of breast cancer in women with neurofibromatosis type 1. British Journal of Cancer, 112(9), 1546-1548. https://doi.org/10.1038/bjc.2015.78
Sestak, I., Dowsett, M., Zabaglo, L., Lopez-Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. (2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. Journal of the National Cancer Institute, 105(19), 1504-1511. https://doi.org/10.1093/jnci/djt244
Seth, A. K., & Cordeiro, P. G. (2020). Stability of Long-Term Outcomes in Implant-Based Breast Reconstruction: An Evaluation of 12-Year Surgeon- and Patient-Reported Outcomes in 3489 Nonirradiated and Irradiated Implants. Plastic and reconstructive surgery, 146(3), 474-484. https://doi.org/10.1097/PRS.0000000000007117
Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., . . . Potter, S. (2020). The Impact of Radiotherapy on Patient-reported Outcomes of Immediate Implant-based Breast Reconstruction With and Without Mesh. Annals of surgery, Jul 9 [Epub ahead of print]. https://doi.org/10.1097/sla.0000000000004245
Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., . . . the Breast Reconstruction Research, C. (2021). Patient-reported outcomes of immediate implant-based breast reconstruction with and without biological or synthetic mesh. BJS Open, 5(1). https://doi.org/10.1093/bjsopen/zraa063
Shannon, C., Ashley, S., & Smith, I. E. (2003). Does timing of adjuvant chemotherapy for early breast cancer influence survival? Journal of clinical oncology, 21(20), 3792-3797.
Sharif, S., Moran, A., Huson, S. M., Iddenden, R., Shenton, A., Howard, E., & Evans, D. G. (2007). Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. Journal of medical genetics, 44(8), 481-484. https://doi.org/10.1136/jmg.2007.049346
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., . . . Winer, E. P. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of clinical oncology, 33(1), 13-21. https://doi.org/10.1200/jco.2014.57.0572
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., . . . Garber, J. E. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of clinical oncology, 28(7), 1145-1153. https://doi.org/10.1200/jco.2009.22.4725
Silverstein, M. J., Poller, D. N., Waisman, J. R., Colburn, W. J., Barth, A., Gierson, E. D., . . . Slamon, D. J. (1995). Prognostic classification of breast ductal carcinoma-in-situ. Lancet, 345(8958), 1154-1157. https://doi.org/10.1016/s0140-6736(95)90982-6
Simon, J. A., Gaines, T., & LaGuardia, K. D. (2016). Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause, 23(11), 1214-1221. https://doi.org/10.1097/gme.0000000000000773
Simpson, J. F., & Page, D. L. (1997). Pathology of preinvasive and excellent-prognosis breast cancer. Current opinion in oncology, 9(6), 512-519. https://doi.org/10.1097/00001622-199711000-00004
Simpson, P. T., Gale, T., Reis-Filho, J. S., Jones, C., Parry, S., Sloane, J. P., . . . Lakhani, S. R. (2005). Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. American journal of surgical pathology, 29(6), 734-746. https://doi.org/10.1097/01.pas.0000157295.93914.3b
Sjöstrom, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson-Lönn, S., Bengtsson, N. O., . . . Bergh, J. (1999). Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. European journal of cancer, 35(8), 1194-1201. https://doi.org/10.1016/s0959-8049(99)00122-7
Skytte, A. B., Cruger, D., Gerster, M., Laenkholm, A. V., Lang, C., Brondum-Nielsen, K., . . . Gerdes, A. M. (2011). Breast cancer after bilateral risk-reducing mastectomy. Clinical Genetics, 79(5), 431-437. https://doi.org/10.1111/j.1399-0004.2010.01604.x
Slamon, D., Eiermann, W., Robert, N., Giermek, J., Martin, M., Jasiowka, M., . . . Investigators, O. B. o. t. B.-. (2016). Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Research, 76(4_Suppl), S5-04. https://doi.org/10.1158/1538-7445.Sabcs15-s5-04
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., . . . Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine, 365(14), 1273-1283. https://doi.org/10.1056/NEJMoa0910383
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182. https://doi.org/10.1126/science.3798106
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., . . . Ullrich, A. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712. https://doi.org/10.1126/science.2470152
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., . . . Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine, 344(11), 783-792. https://doi.org/Doi 10.1056/Nejm200103153441101
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., . . . Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 382(6), 514-524. https://doi.org/10.1056/NEJMoa1911149
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., . . . Jerusalem, G. (2018). Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of clinical oncology, 36(24), 2465-2472. https://doi.org/10.1200/jco.2018.78.9909
Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2020). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA oncology, 6(1), 116-124. https://doi.org/10.1001/jamaoncol.2019.4782
Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of clinical oncology, 35(25), 2875-2884. https://doi.org/10.1200/jco.2017.73.7585
Sobti, N., Weitzman, R. E., Nealon, K. P., Jimenez, R. B., Gfrerer, L., Mattos, D., . . . Liao, E. C. (2020). Evaluation of capsular contracture following immediate prepectoral versus subpectoral direct-to-implant breast reconstruction. Scientific reports, 10(1), 1137. https://doi.org/10.1038/s41598-020-58094-4
Sorrentino, L., Regolo, L., Scoccia, E., Petrolo, G., Bossi, D., Albasini, S., . . . Corsi, F. (2019). Autologous fat transfer after breast cancer surgery: An exact-matching study on the long-term oncological safety. European journal of surgical oncology. https://doi.org/10.1016/j.ejso.2019.05.013
Sotiriou, C., Lacroix, M., Lespagnard, L., Larsimont, D., Paesmans, M., & Body, J. J. (2001). Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer letters, 169(1), 87-95. https://doi.org/10.1016/s0304-3835(01)00524-9
Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., . . . Milne, R. L. (2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of medical genetics, 53(12), 800-811. https://doi.org/10.1136/jmedgenet-2016-103839
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine, 379(2), 111-121. https://doi.org/10.1056/NEJMoa1804710
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W. (2015). Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine, 373(21), 2005-2014. https://doi.org/10.1056/NEJMoa1510764
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., . . . Sledge, G. W., Jr. (2019). Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England journal of medicine, 380(25), 2395-2405. https://doi.org/10.1056/NEJMoa1904819
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., . . . Davidson, N. E. (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England journal of medicine, 358(16), 1663-1671. https://doi.org/10.1056/NEJMoa0707056
Spear, S. L., Coles, C. N., Leung, B. K., Gitlin, M., Parekh, M., & Macarios, D. (2016). The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast Surgery. Plastic and reconstructive surgery. Global open, 4(8), e827. https://doi.org/10.1097/GOX.0000000000000842
Speck, R. M., Courneya, K. S., Masse, L. C., Duval, S., & Schmitz, K. H. (2010). An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Journal of cancer survivorship : research and practice, 4(2), 87-100. https://doi.org/10.1007/s11764-009-0110-5
Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., . . . Bardia, A. (2016). Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA oncology, 2(11), 1477-1486. https://doi.org/10.1001/jamaoncol.2016.1897
Spronk, I., Schellevis, F. G., Burgers, J. S., de Bock, G. H., & Korevaar, J. C. (2018). Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. Breast, 39, 70-79. https://doi.org/10.1016/j.breast.2018.03.011
Stark, B., Magneli, M., van Heijningen, I., Parreira, C., Bosch, U., Rouif, M., & Halle, M. (2021). Considerations on the Demography of BIA-ALCL in European Countries Based on an E(A)SAPS Survey. Aesthetic Plast Surg, 45(6), 2639-2644. https://doi.org/10.1007/s00266-021-02411-3
Statens legemiddelverk. (2012). Refusjonsrapport: denosumab (Xgenva) til forebygging av skjelett-realterte hendelser hos voksne med benmetastaser fra solide tumorer: vurdering av søknad om forhåndsgodkjent refusjon §2. Oslo: Statens legemiddelverk. Hentet fra https://www.nyemetoder.no/siteassets/documents/Rapporter/Denosumab_helseokonomisk-vurdering-2012.pdf
Stensheim, H., Cvancarova, M., Møller, B., & Fosså, S. D. (2011). Pregnancy after adolescent and adult cancer: A population-based matched cohort study. International Journal of Cancer, 129(5), 1225-1236. https://doi.org/10.1002/ijc.26045
Stokes, E. L., Tyldesley, S., Woods, R., Wai, E., & Olivotto, I. A. (2011). Effect of nodal irradiation and fraction size on cardiac and cerebrovascular mortality in women with breast cancer treated with local and locoregional radiotherapy. International journal of radiation oncology, biology, physics, 80(2), 403-409. https://doi.org/10.1016/j.ijrobp.2010.02.041
Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., . . . Braun, A. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of clinical oncology, 28(35), 5132-5139. https://doi.org/10.1200/JCO.2010.29.7101
Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., . . . Polgar, C. (2016). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, 387(10015), 229-238. https://doi.org/10.1016/s0140-6736(15)00471-7
Stuart, K. E., Houssami, N., Taylor, R., Hayen, A., & Boyages, J. (2015). Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer, 15, 890. https://doi.org/10.1186/s12885-015-1904-7
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reutersward, C., Hakkinen, J., . . . Nik-Zainal, S. (2019). Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature medicine, 25(10), 1526-1153. https://doi.org/10.1038/s41591-019-0582-4
Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., . . . Cortes, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine, 372(8), 724-734. https://doi.org/10.1056/NEJMoa1413513
Swain, S. M., Jeong, J. H., Geyer, C. E., Jr., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Wolmark, N. (2010). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. The New England journal of medicine, 362(22), 2053-2065. https://doi.org/10.1056/NEJMoa0909638
Swain, S. M., Kim, S. B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., . . . Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology, 14(6), 461-471. https://doi.org/10.1016/S1470-2045(13)70130-X
Tabar, L., Vitak, B., Chen, H. H., Yen, M. F., Duffy, S. W., & Smith, R. A. (2001). Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer, 91(9), 1724-1731. https://doi.org/10.1002/1097-0142(20010501)91:9<1724::aid-cncr1190>3.0.co;2-v
Takeda, A., Shigematsu, N., Kondo, M., Amemiya, A., Kawaguchi, O., Sato, M., . . . Kubo, A. (2000). The modified tangential irradiation technique for breast cancer: how to cover the entire axillary region. International journal of radiation oncology, biology, physics, 46(4), 815-822. https://doi.org/Doi 10.1016/S0360-3016(99)00463-0
Tamura, K., Imamura, C. K., Takano, T., Saji, S., Yamanaka, T., Yonemori, K., . . . Tanigawara, Y. (2020). CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. Journal of clinical oncology, 38(6), 558-566. https://doi.org/10.1200/JCO.19.01412
Tan, A. R., Im, S. A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., . . . Jackisch, C. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 22(1), 85-97. https://doi.org/10.1016/s1470-2045(20)30536-2
Tan, P. H., Thike, A. A., Tan, W. J., Thu, M. M., Busmanis, I., Li, H., . . . Tan, M. H. (2012). Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of clinical pathology, 65(1), 69-76. https://doi.org/10.1136/jclinpath-2011-200368
Tanbo, T., Greggains, G., Storeng, R., Busund, B., Langebrekke, A., & Fedorcsak, P. (2015). Autotransplantation of cryopreserved ovarian tissue after treatment for malignant disease – the first Norwegian results. Acta Obstetricia et Gynecologica Scandinavica, 94(9), 937-941. https://doi.org/10.1111/aogs.12700
Tang, R., Coopey, S. B., Colwell, A. S., Specht, M. C., Gadd, M. A., Kansal, K., . . . Smith, B. L. (2015). Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications. Annals of surgical oncology, 22(10), 3331-3337. https://doi.org/10.1245/s10434-015-4669-y
Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., . . . McGale, P. (2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of clinical oncology, 35(15), 1641-1649. https://doi.org/10.1200/jco.2016.72.0722
Taylor, C., McGale, P., Bronnum, D., Correa, C., Cutter, D., Duane, F. K., . . . Ewertz, M. (2018). Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. Journal of clinical oncology, 36(22), 2288-2296. https://doi.org/10.1200/jco.2017.77.6351
Taylor, C. W., Brønnum, D., Darby, S. C., Gagliardi, G., Hall, P., Jensen, M. B., . . . Ewertz, M. (2011). Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977-2001. Radiotherapy and Oncology, 100(2), 176-183. https://doi.org/10.1016/j.radonc.2011.01.020
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., . . . Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical cancer research, 22(15), 3764-3773. https://doi.org/10.1158/1078-0432.CCR-15-2477
Thamm, O. C., & Andree, C. (2018). Immediate Versus Delayed Breast Reconstruction: Evolving Concepts and Evidence Base. Clinics in plastic surgery, 45(1), 119-127. https://doi.org/10.1016/j.cps.2017.08.010
The American Society of Breast surgeons. (2018). Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions. Columbia, MD: The American Society of Breast surgeons. Hentet fra https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Gluck, S., Stewart, J. F., . . . Reitsma, D. J. (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. Journal of clinical oncology, 17(3), 846-854. https://doi.org/10.1200/JCO.1999.17.3.846
Theriault, R. L., & Litton, J. K. (2013). Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? Journal of clinical oncology, 31(20), 2521-2522. https://doi.org/10.1200/jco.2013.49.7347
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., . . . Liu, E. T. (1998). erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute, 90(18), 1346-1360. https://doi.org/10.1093/jnci/90.18.1346
Thorarinsson, A., Frojd, V., Kolby, L., Ljungdal, J., Taft, C., & Mark, H. (2017). Long-Term Health-Related Quality of Life after Breast Reconstruction: Comparing 4 Different Methods of Reconstruction. Plastic and reconstructive surgery. Global open, 5(6), e1316. https://doi.org/10.1097/GOX.0000000000001316
Thorsen, L. B., Offersen, B. V., Danø, H., Berg, M., Jensen, I., Pedersen, A. N., . . . Overgaard, J. (2016). DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. Journal of clinical oncology, 34(4), 314-320. https://doi.org/10.1200/jco.2015.63.6456
Thorsen, L. B. J., Overgaard, J., Matthiessen, L. W., Berg, M., Stenbygaard, L., Pedersen, A. N., . . . Offersen, B. V. (2022). Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study. Journal of clinical oncology, Epub ahead of print. https://doi.org/10.1200/jco.22.00044
Thune, I. (2008). Kreft. I: R. Bahr (red.), Aktivitetshåndboken: fysisk aktivitet i forebygging og behandling (s. 359-370). Oslo: Helsedirektoratet.
Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., & Bundred, N. (2017). Comparison of Local Recurrence After Simple and Skin-Sparing Mastectomy Performed in Patients with Ductal Carcinoma In Situ. Annals of surgical oncology, 24(4), 1071-1076. https://doi.org/10.1245/s10434-016-5673-6
Tjan-Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., . . . Seynaeve, C. M. (2017). Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. The Lancet. Oncology, 18(11), 1502-1511. https://doi.org/10.1016/s1470-2045(17)30600-9
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., . . . Winer, E. P. (2015). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England journal of medicine, 372(2), 134-141. https://doi.org/10.1056/NEJMoa1406281
Tolaney, S. M., Barry, W. T., Guo, H., Dillon, D., Dang, C. T., Yardley, D. A., . . . Winer, E. P. (2017). Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology, 35(15 suppl), 511. https://doi.org/10.1200/JCO.2017.35.15_suppl.511
Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., . . . Winer, E. P. (2019). Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of clinical oncology, 37(22), 1868-1875. https://doi.org/10.1200/jco.19.00066
Tolaney, S. M., Wardley, A. M., Zambelli, S., Hilton, J. F., Troso-Sandoval, T. A., Ricci, F., . . . Andre, F. (2020). Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. The Lancet. Oncology, 21(6), 763-775. https://doi.org/10.1016/S1470-2045(20)30112-1
Torres, L. M., Yuste Sanchez, M. J., Zapico, G. A., Prieto, M. D., Mayoral del, M. O., Cerezo, T. E., & Minayo, M. E. (2010). Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ, 340, b5396.
Toulis, K. A., Tzellos, T., Kouvelas, D., & Goulis, D. G. (2009). Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clinical therapeutics, 31(2), 221-235. https://doi.org/10.1016/j.clinthera.2009.02.006
Trainer, A. H., Lewis, C. R., Tucker, K., Meiser, B., Friedlander, M., & Ward, R. L. (2010). The role of BRCA mutation testing in determining breast cancer therapy. Nature reviews. Clinical oncology, 7(12), 708-717. https://doi.org/10.1038/nrclinonc.2010.175
Tripathy, D., Im, S. A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., . . . Lu, Y. S. (2018). Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet. Oncology, 19(7), 904-915. https://doi.org/10.1016/s1470-2045(18)30292-4
Trudeau, M., Charbonneau, F., Gelmon, K., Laing, K., Latreille, J., Mackey, J., . . . Verma, S. (2005). Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. The Lancet. Oncology, 6(11), 886-898. https://doi.org/10.1016/S1470-2045(05)70424-1
Tsao, M. N., Rades, D., Wirth, A., Lo, S. S., Danielson, B. L., Gaspar, L. E., . . . Chang, E. L. (2012). Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Practical radiation oncology, 2(3), 210-225. https://doi.org/10.1016/j.prro.2011.12.004
Tsoutsou, P. G., Koukourakis, M. I., Azria, D., & Belkacemi, Y. (2009). Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Critical Reviews in Oncology/Hematology, 71(2), 102-116. https://doi.org/10.1016/j.critrevonc.2008.09.002
Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., . . . Robson, M. E. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Clinical oncology, 13(9), 581-588. https://doi.org/10.1038/nrclinonc.2016.90
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., . . . Zakalik, D. (2020). Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. Journal of clinical oncology, 38(18), 2080-2106. https://doi.org/10.1200/jco.20.00299
Turnbull, L., Brown, S., Harvey, I., Olivier, C., Drew, P., Napp, V., . . . Brown, J. (2010). Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet, 375(9714), 563-571. https://doi.org/10.1016/s0140-6736(09)62070-5
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., . . . Reis-Filho, J. S. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene, 29(14), 2013-2023. https://doi.org/10.1038/onc.2009.489
Turner, N., Tutt, A., & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews. Cancer, 4(10), 814-819. https://doi.org/10.1038/nrc1457
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., . . . Cristofanilli, M. (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine, 373(3), 209-219. https://doi.org/10.1056/NEJMoa1505270
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., . . . Cristofanilli, M. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 379(20), 1926-1936. https://doi.org/10.1056/NEJMoa1810527
Turner, S., Chia, S., Kanakamedala, H., Hsu, W. C., Park, J., Chandiwana, D., . . . Rugo, H. S. (2021). Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Oncologist, 26(7), e1133-e1142. https://doi.org/10.1002/onco.13804
Turton, P., El-Sharkawi, D., Lyburn, I., Sharma, B., Mahalingam, P., Turner, S. D., . . . Mercer, N. (2021). UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 74(1), 13-29. https://doi.org/10.1016/j.bjps.2020.10.064
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., . . . Bliss, J. M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine, 24(5), 628-637. https://doi.org/10.1038/s41591-018-0009-7
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., . . . Geyer, C. E., Jr. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England journal of medicine, 384(25), 2394-2405. https://doi.org/10.1056/NEJMoa2105215
Untch, M., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., . . . Loibl, S. (2015). Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe und Frauenheilkunde, 75(6), 556-565. https://doi.org/10.1055/s-0035-1546120
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., . . . Loibl, S. (2019). NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. Journal of clinical oncology, 37(25), 2226-2234. https://doi.org/10.1200/jco.18.01842
Uusitalo, E., Rantanen, M., Kallionpää, R. A., Pöyhönen, M., Leppävirta, J., Ylä-Outinen, H., . . . Peltonen, J. (2016a). Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. Journal of clinical oncology, 34(17), 1978-1986. https://doi.org/10.1200/jco.2015.65.3576
Uusitalo, E., Rantanen, M., Kallionpaa, R. A., Poyhonen, M., Leppavirta, J., Yla-Outinen, H., . . . Peltonen, J. (2016b). Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. Journal of clinical oncology, 34(17), 1978-1986. https://doi.org/10.1200/JCO.2015.65.3576
Vaidya, J. S., Bulsara, M., Baum, M., Wenz, F., Massarut, S., Pigorsch, S., . . . Tobias, J. S. (2020). Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836
Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., . . . Baum, M. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet, 376(9735), 91-102. https://doi.org/10.1016/s0140-6736(10)60837-9
Valachis, A., Nearchou, A. D., & Lind, P. (2014). Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast cancer research and treatment, 144(3), 443-455. https://doi.org/10.1007/s10549-014-2890-1
Van Calsteren, K., Heyns, L., De Smet, F., Van Eycken, L., Gziri, M. M., Van Gemert, W., . . . Amant, F. (2010). Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. Journal of clinical oncology, 28(4), 683-689. https://doi.org/10.1200/jco.2009.23.2801
van Dalen, E. C., Michiels, E. M., Caron, H. N., & Kremer, L. C. (2010). Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane database of systematic reviews, (5), CD005006. https://doi.org/10.1002/14651858.CD005006.pub4
van der Voort, A., van Ramshorst, M. S., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Vulink, A. J., . . . Sonke, G. S. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA oncology, 7(7), 978-984. https://doi.org/10.1001/jamaoncol.2021.1371
van Hellemond, I. E. G., Vriens, I. J. H., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., Seynaeve, C. M., . . . Tjan-Heijnen, V. C. G. (2017). Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. Journal of the National Cancer Institute, 109(12). https://doi.org/10.1093/jnci/djx074
van Mackelenbergh, M., Seither, F., Möbus, V., Shaugnessy, J., Martin, M., Joenssuu, H., . . . Loibl, S. (2020). Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Research, 80(4 Suppl), GS1-07. https://doi.org/10.1158/1538-7445.SABCS19-GS1-07
van Tienhoven, G., Voogd, A. C., Peterse, J. L., Nielsen, M., Andersen, K. W., Mignolet, F., . . . van Dongen, J. A. (1999). Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. European journal of cancer, 35(1), 32-38. https://doi.org/10.1016/s0959-8049(98)00301-3
Varghese, J., Gohari, S. S., Rizki, H., Faheem, M., Langridge, B., Kummel, S., . . . Schmid, P. (2021). A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. Breast, 55, 55-62. https://doi.org/10.1016/j.breast.2020.11.023
Varshavsky-Yanovsky, A. N., & Goldstein, L. J. (2020). Role of Capecitabine in Early Breast Cancer. Journal of clinical oncology, 38(3), 179-182. https://doi.org/10.1200/jco.19.02946
Venturini, M., Del Mastro, L., Aitini, E., Baldini, E., Caroti, C., Contu, A., . . . Bruzzi, P. (2005). Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. Journal of the National Cancer Institute, 97(23), 1724-1733. https://doi.org/10.1093/jnci/dji398
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., . . . Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 367(19), 1783-1791. https://doi.org/10.1056/NEJMoa1209124
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., . . . Marubini, E. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. The New England journal of medicine, 347(16), 1227-1232. https://doi.org/10.1056/NEJMoa020989
Veronesi, U., Marubini, E., Del Vecchio, M., Manzari, A., Andreola, S., Greco, M., . . . Rilke, F. (1995). Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. Journal of the National Cancer Institute, 87(1), 19-27. https://doi.org/10.1093/jnci/87.1.19
Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., . . . Gennari, R. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. The New England journal of medicine, 349(6), 546-553. https://doi.org/10.1056/NEJMoa012782
Vicini, F. A., Cecchini, R. S., White, J. R., Arthur, D. W., Julian, T. B., Rabinovitch, R. A., . . . Wolmark, N. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, 394(10215), 2155-2164. https://doi.org/10.1016/s0140-6736(19)32514-0
Vidal, L., Ben-Aharon, I., Shulamith, R., Yerushalmi, R., Sulkes, A., & Stemmer, S. M. (2012). Bisphosphonates in the adjuvant setting of breast cancer therapy: Effect on survival--A systematic review and meta-analysis. Journal of clinical oncology, 30(15 Supplement), 548.
Virnig, B. A., Tuttle, T. M., Shamliyan, T., & Kane, R. L. (2010). Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. Journal of the National Cancer Institute, 102(3), 170-178. https://doi.org/10.1093/jnci/djp482
Vitek, W. S., Shayne, M., Hoeger, K., Han, Y., Messing, S., & Fung, C. (2014). Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertility and Sterility, 102(3), 808-815.e801. https://doi.org/10.1016/j.fertnstert.2014.06.003
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., . . . Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of clinical oncology, 20(3), 719-726. https://doi.org/Doi 10.1200/Jco.20.3.719
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., . . . Loibl, S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. Journal of clinical oncology, 27(12), 1999-2006. https://doi.org/10.1200/JCO.2008.19.6618
von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., . . . Geyer, C. E., Jr. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England journal of medicine, 380(7), 617-628. https://doi.org/10.1056/NEJMoa1814017
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., . . . Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. The New England journal of medicine, 377(2), 122-131. https://doi.org/10.1056/NEJMoa1703643
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., . . . Untch, M. (2014). Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. The Lancet. Oncology, 15(7), 747-756. https://doi.org/10.1016/s1470-2045(14)70160-3
von Schoultz, E., & Rutqvist, L. E. (2005). Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. Journal of the National Cancer Institute, 97(7), 533-535. https://doi.org/10.1093/jnci/dji071
Waks, A. G., & Partridge, A. H. (2016). Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety. Journal of the National Comprehensive Cancer Network : JNCCN, 14(3), 355-363. https://doi.org/10.6004/jnccn.2016.0038
Wallis, M., Tardivon, A., Helbich, T., & Schreer, I. (2007). Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. European radiology, 17(2), 581-588. https://doi.org/10.1007/s00330-006-0408-x
Wang, F., Peled, A. W., Chin, R., Fowble, B., Alvarado, M., Ewing, C., . . . Sbitany, H. (2016). The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction. Plastic and reconstructive surgery, 137(1), 1-9. https://doi.org/10.1097/PRS.0000000000001866
Wang, K., Dai, Y., Pan, Y., Cheng, P., & Jin, X. (2020). Local-regional recurrence risk after autologous fat grafting in breast cancer patients: A systematic review and meta-analysis. Journal of surgical oncology, 121(3), 435-440. https://doi.org/10.1002/jso.25829
Wapnir, I. L., Gelber, S., Anderson, S. J., Mamounas, E. P., Robidoux, A., Martin, M., . . . Aebi, S. (2017). Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Annals of surgical oncology, 24(2), 398-406. https://doi.org/10.1245/s10434-016-5571-y
Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., . . . Aebi, S. (2018). Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. Journal of clinical oncology, 36(11), 1073-1079. https://doi.org/10.1200/jco.2017.76.5719
Warne, G. L., Fairley, K. F., Hobbs, J. B., & Martin, F. I. (1973). Cyclophosphamide-induced ovarian failure. The New England journal of medicine, 289(22), 1159-1162. https://doi.org/10.1056/NEJM197311292892202
Wassermann, J., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Schapira, L., . . . Partridge, A. H. (2019). Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer, 125(18), 3266-3274. https://doi.org/10.1002/cncr.32192
Wazir, U., El Hage Chehade, H., Headon, H., Oteifa, M., Kasem, A., & Mokbel, K. (2016). Oncological Safety of Lipofilling in Patients with Breast Cancer: A Meta-analysis and Update on Clinical Practice. Anticancer research, 36(9), 4521-4528. https://doi.org/10.21873/anticanres.10999
Weaver, D. L., Ashikaga, T., Krag, D. N., Skelly, J. M., Anderson, S. J., Harlow, S. P., . . . Wolmark, N. (2011). Effect of occult metastases on survival in node-negative breast cancer. The New England journal of medicine, 364(5), 412-421. https://doi.org/10.1056/NEJMoa1008108
Westling, P., Svensson, H., & Hele, P. (1972). Cervical plexus lesions following post-operative radiation therapy of mammary carcinoma. Acta radiologica: therapy, physics, biology, 11(3), 209-216. https://doi.org/10.3109/02841867209130761
Whelan, T. J., Julian, J. A., Berrang, T. S., Kim, D. H., Germain, I., Nichol, A. M., . . . Olivotto, I. A. (2019). External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet, 394(10215), 2165-2172. https://doi.org/10.1016/s0140-6736(19)32515-2
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., . . . Levine, M. N. (2015). Regional Nodal Irradiation in Early-Stage Breast Cancer. The New England journal of medicine, 373(4), 307-316. https://doi.org/10.1056/NEJMoa1415340
Whelan, T. J., Pignol, J. P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., . . . Freeman, C. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. The New England journal of medicine, 362(6), 513-520. https://doi.org/10.1056/NEJMoa0906260
Widner, N., & Dabbs, D. J. (2012). Metaplastic breast carcinoma. I: D. J. Dabbs (red.), Breast pathology (s. 479-501). Philadelphia, PA: Elsevier (Saunders).
Wilcken, N., Hornbuckle, J., & Ghersi, D. (2003). Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane database of systematic reviews, (2), CD002747. https://doi.org/10.1002/14651858.CD002747
Wilkinson, G. S., Kuo, Y. F., Freeman, J. L., & Goodwin, J. S. (2007). Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. Journal of the National Cancer Institute, 99(13), 1016-1024. https://doi.org/10.1093/jnci/djm025
Wilkosz, P., Greggains, G. D., Tanbo, T. G., & Fedorcsak, P. (2014). Female Reproductive Decline Is Determined by Remaining Ovarian Reserve and Age. PLoS ONE, 9(10), e108343. https://doi.org/10.1371/journal.pone.0108343
Willey, S. C., Fan, K. L., Luvisa, K., Graziano, F. D., Lau, S. H. Y., Black, C. K., . . . Pittman, T. (2020). Predicting Ischemic Complications in the Inframammary Approach to Nipple-Sparing Mastectomy: The Midclavicular-to-Inframammary Fold Measurement. Plastic and reconstructive surgery, 145(2), 251e-262e. https://doi.org/10.1097/PRS.0000000000006439
Willner, J., Kiricuta, I. C., & Kolbl, O. (1997). Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. International journal of radiation oncology, biology, physics, 37(4), 853-863.
Willner, J., Kiricuta, I. C., Kolbl, O., & Flentje, M. (1999). Long-term survival following postmastectomy locoregional recurrence of breast cancer. Breast, 8(4), 200-204. https://doi.org/10.1054/brst.1999.0033
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., . . . Delorenzi, M. (2008). Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research, 10(4), R65. https://doi.org/10.1186/bcr2124
Wist, E. (2000). Onkologisk akuttilstander. I: R. Kåresen & E. Wist (red.), Kreftsykdommer: en basisbok for helsepersonell (s. 90-95). Oslo: Gyldendal akademisk.
Wist, E. A., Sommer, H. H., Østenstad, B., Risberg, T., Bremnes, Y., & Mjaaland, I. (2004a). Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncologica, 43(2), 186-189. https://doi.org/10.1080/02841860310023165
Wist, E. A., Sommer, H. H., Østenstad, B., Risberg, T., & Fjæstad, K. (2004b). Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncologica, 43(1), 11-14. https://doi.org/10.1080/02841860310017748
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., . . . Dowsett, M. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of clinical oncology, 36(20), 2105-2122. https://doi.org/10.1200/jco.2018.77.8738
Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Tsuchiya, K. (2014). Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet. Oncology, 15(4), 387-395. https://doi.org/10.1016/s1470-2045(14)70061-0
Yao, K., Liederbach, E., Tang, R., Lei, L., Czechura, T., Sisco, M., . . . Smith, B. L. (2015). Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Annals of surgical oncology, 22(2), 370-376. https://doi.org/10.1245/s10434-014-3883-3
Yap, Y. S., Munusamy, P., Lim, C., Chan, C. H. T., Prawira, A., Loke, S. Y., . . . Lee, A. S. G. (2018). Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype. Breast cancer research and treatment, 171(3), 719-735. https://doi.org/10.1007/s10549-018-4851-6
Yardley, D. A., Burris, H. A., III, Simons, L., Spigel, D. R., Greco, F. A., Barton, J. H., . . . Hainsworth, J. D. (2008). A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clinical breast cancer, 8(5), 425-431. https://doi.org/10.3816/CBC.2008.n.051
Yazar, S., Bengur, F. B., Altinkaya, A., Kara, H., & Uras, C. (2021). Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction with or Without Skin Reduction in Patients with Large Ptotic Breasts: A Case-Matched Analysis. Aesthetic Plast Surg, 45(3), 956-967. https://doi.org/10.1007/s00266-020-02000-w
Yen, M. F., Tabar, L., Vitak, B., Smith, R. A., Chen, H. H., & Duffy, S. W. (2003). Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. European journal of cancer, 39(12), 1746-1754. https://doi.org/10.1016/s0959-8049(03)00260-0
Yu, K. D., Liu, X. Y., Chen, L., Mo, M., Wu, J., Liu, G. Y., . . . Shao, Z. M. (2021). Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. The Lancet regional health. Western Pacific, 11, 100158. https://doi.org/10.1016/j.lanwpc.2021.100158
Yu, K. D., Ye, F. G., He, M., Fan, L., Ma, D., Mo, M., . . . Shao, Z. M. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology, 6(9), 1390-1396. https://doi.org/10.1001/jamaoncol.2020.2965
Zaenger, D., Rabatic, B. M., Dasher, B., & Mourad, W. F. (2016). Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? Clinical breast cancer, 16(2), 101-104. https://doi.org/10.1016/j.clbc.2015.11.005
Zagouri, F., Sergentanis, T. N., Azim, H. A., Jr., Chrysikos, D., Dimopoulos, M. A., & Psaltopoulou, T. (2015). Aromatase inhibitors in male breast cancer: a pooled analysis. Breast cancer research and treatment, 151(1), 141-147. https://doi.org/10.1007/s10549-015-3356-9
Zhan, Q. H., Fu, J. Q., Fu, F. M., Zhang, J., & Wang, C. (2018). Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget, 9(2), 2739-2751. https://doi.org/10.18632/oncotarget.23086
Zhang, F. F., Haslam, D. E., Terry, M. B., Knight, J. A., Andrulis, I. L., Daly, M. B., . . . John, E. M. (2017). Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer, 123(11), 2070-2079. https://doi.org/10.1002/cncr.30615
Zhang, H., Li, Y., Moran, M. S., Haffty, B. G., & Yang, Q. (2015). Predictive factors of nipple involvement in breast cancer: a systematic review and meta-analysis. Breast cancer research and treatment, 151(2), 239-249. https://doi.org/10.1007/s10549-015-3385-4
Zhang, L., Jin, K., Wang, X., Yang, Z., Wang, J., Ma, J., . . . Guo, X. (2019). The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction. Annals of surgical oncology, 26(4), 961-968. https://doi.org/10.1245/s10434-018-07135-4
Zhang, X., Liu, W., Hai, T., & Li, F. (2021). Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis. Annals of surgical oncology, 28(13), 8643-8650. https://doi.org/10.1245/s10434-021-10188-7
Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., . . . Treatment of, C. (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European journal of cancer, 47(1), 8-32. https://doi.org/10.1016/j.ejca.2010.10.013
Aas, T., Geisler, S., Paulsen, T., Borresen-Dale, A. L., Varhaug, J. E., Lonning, P. E., & Akslen, L. A. (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica, 35(Suppl 5), 5-8. https://doi.org/10.3109/02841869609083960